

Controversies in Plastic Surgery: Suction-Assisted Lipectomy (SAL) and the hCG (Human Chorionic Gonadotropin) Protocol for Obesity Treatment

Trudy Vogt, M.D. and Daniel Belluscio, M.D.

Zürich, Switzerland

Abstract. The advent of SAL (suction-assisted lipectomy) has dramatically increased the number of obese patients coming to our consultation offices. Despite several articles suggesting a conservative approach to fat suction, some reports insinuate that SAL might be a useful tool for obesity treatment. This hypothesis is refuted by a vast body of evidence that concludes that the adipose tissue may regenerate in adult humans. Therefore, surgical procedures are not advised as the method of choice to manage the disease. On the other hand, the terms obesity and being overweight may not be interchangeable. Obesity may be a disease whereas being overweight is a *sign* of the disease. Consequently, proper preoperative selection of candidates for SAL becomes mandatory. The hCG (human chorionic gonadotropin) method for obesity treatment appears to be a complete program for the management of obesity. It contains pharmacologic, dietetic, and behavior modification aspects in a 40-day course of treatment. Some data suggest hCG to be lipolytic, thus explaining former clinical observations regarding body fat redistribution in treated patients. hCG commercial preparations contain β -endorphin, an opioid peptide linked to mood behavior. This article speculates on the possible actions of the complex hCG β -endorphin in the neuromodulation of mood and energy metabolism. The method comprises a behavior modification that helps in handling the patient better. There are some correlations between a current behavior modification program and the basic guidelines contained in the hCG protocol. Thus, the hCG method appears to be a reasonable alternative in the management of a long-standing, unsolved problem of human metabolism.

Key words: Adipose tissue — Metabolism — Endorphins — physiology — Obesity, treatment — Gonad-

otropin(s), chorionic, pharmacodynamics — Gonadotropin(s), chorionic, therapeutic use

Introduction

SAL (Suction-Assisted Lipectomy) and Obesity

Few surgical procedures aroused as much interest from plastic surgeons and the lay press as SAL did. Pioneered by the early reports of Fischer and Fischer [103] and Schrudde [273], SAL reached its heyday after the publications of Illouz [159–162] and Kesselring [186–189]. Actually, SAL has become the “prima donna” in the surgical armamentarium of plastic surgeons, and nearly no part of the human anatomy is spared, including the thighs, knees, neck, buttocks, calves, arms, breasts, flaps, back, and abdomen. Patients under and over the age of 50 have, therefore, experienced the back-and-forth movement of a cannula connected to a suction pump [72–73b, 107, 128, 145–146, 186–189, 250, 308a–b, 326]. Cautious words about SAL are scarce [69, 124, 322] compared with the myriad of enthusiastic reports. The number of SAL performed surpasses any other aesthetic surgical procedure and this tendency is growing [4].

Nevertheless, because SAL is a novel surgical technique, its precise indications remain the center of dispute. Articles have been published that propose a conservative approach to fat suction, whereas diverse publications suggest SAL may be an useful tool in the therapy of obesity [241]. The differences between the criteria are not of mere academic interest. If SAL is the appropriate maneuver




Fig. 1. Android (**left**) and gynoid (**right**) types of obesity




Fig. 2. The hypothetical long-term result from an overzealous SAL. Patient with a classical gynoid-type of obesity (**left**) showing waviness in thighs region and an android redistribution of fat after a SAL (**right**). This “new” body fat distribution forewarns a higher incidence of metabolic complications

for the management of the obesity, then plastic surgeons would receive the merit of having developed an easy procedure that solves a disease that has been present for thousands of years. But if SAL is *not* the adequate method for obesity therapy, then preoperative patient *selection* becomes of utmost importance.

Body Fat Distribution and SAL

Fat suction might have adverse effects in obese patients: it is well known from Vague's report that there exist two types of obesity, depending on body fat distribution: a gynoid type and an android type [312, 314] (Fig. 1). The gynoid type of obesity tends to accumulate fat in the hips, buttocks, thighs, and lower abdomen. In the android type, adipose tissue largely localizes in the back, shoulders, and upper abdomen. Gynoid fatness is more resistant to dieting. The android type is easier to treat but shows an increased incidence of clinical complications, such as hyperlipemia, hypercholesterolemia, diabetes, hypertension, diabetes, and gout [313, 316].

Excessive fat removal by SAL may stimulate, in the long run, counterregulatory balances resulting in adipocyte hypertrophy and/or hyperplasia from the adipocytary pool. Faust and Kral concluded: “. . . rapid weight gain after a lipectomy cannot involve tissue that is no longer present, so it may require hypertrophy of the remaining tissues.” [96]. In the case of gynoid obesity, this compensatory growth after a lipectomy (or an overzealous SAL)

may occur in the upper part of the body. Thus, by force of surgical treatment a “cosmetic” obesity may evolve into a “medical” one [Fig. 2]. This modification of body fat distribution certainly does not benefit the patient. When compared with gynoid fatness, the android type of obesity shows an increased cardiovascular risk [313, 316].

Alternatively, counterregulatory mechanisms may generate adipocytary hypertrophy and/or hyperplasia in the liposuctioned area. Figure 3 shows an obese patient twice liposuctioned elsewhere, showing recurrence both of obesity and body contour deformity.

In our opinion, SAL has a definite place in body contour surgery provided that it is performed in small quantities, in conspicuous fat accumulations, and for an aesthetic improvement of the body contour (Fig. 4) [325]. Therefore, today's plastic surgeons should bear the responsibility for selecting those patients who would benefit from a preoperative weight reduction program. During the past seven years we have insisted that candidates for a body contour surgical procedure should correct their obese condition prior to the operation itself [319–325]. This is imperative, because of the increased numbers of moderately obese patients coming to our consultation offices.

In our experience, a most difficult issue is the selection of an adequate obesity therapy suitable to our plastic surgical requirements as well. Weight reduction programs offering an acceptable weight loss but poor skin tone are fairly common (Fig. 5).

After many trials, we concluded that the hCG (human chorionic gonadotropin) program suited our




Fig. 3. Obese patient twice liposuctioned elsewhere showing recurrence of obesity and body contour deformity




Fig. 4 (A–C). Ideal anatomic sites to perform a conservative SAL

needs and goals: rapid weight loss, excellent body contour, and good skin tone after treatment (Fig. 6). As is well known, this striking approach to obesity provoked several years ago a growing wave of criticism [6, 14, 19, 28, 42, 60, 61, 74, 108, 130, 140, 224, 247, 256, 276, 294, 337]. Nevertheless, because of recent data suggesting hCG might be lipolytic *in vivo*, we believe the whole subject deserves a new evaluation. For this objective we have mapped out a working hypothesis on the subject. Consequently, the purposes of this article are (1) briefly review some new trends on obesity classifications and summarize current concepts on obesity and adipose tis-

sue metabolism and (2) discuss several lines of evidence that suggest that the hCG method is a complete pharmacologic, dietetic, and behavioral modification program for obesity treatment.

Part I: Overview of Obesity and Adipose Tissue

“Observe that the things which are considered to be right today are those which were considered to be impossible yesterday. The things which are thought wrong today are those which will be esteemed right tomorrow.”
Hudhaifa




Fig. 5 (A,B). Aesthetic result in a patient treated with a standard hypocaloric diet. Weight loss was 20 kg




Fig. 6. Patient before (A) and after (B) a full course of treatment (40 days) under the hCG program. Weight loss was 16.3 kg

OBESITY

Classification of Obesity

Clinical signs other than weight and height are currently relevant in the assessment of the obese pa-

tient. A considerable body of evidence suggests that fat distribution plays a prognostic role in the evaluation of the disorder of obesity. As mentioned before, Vague's report was a major advance on the subject. Similar conclusions regarding the clinical importance of body fat topography were put forward by several authors. Kissebah's laboratory




Fig. 7. Abdominal (A) and gluteofemora, (B) types of obesity. (Redrawn from [11])

classified the obesities in UBSO (upper body segmental obesity) and LBSO (lower body segmental obesity) [92]: UBSO is characterized by a WHR (waist to hip ratio, the relationship between waist and hip circumference) close to or above 1. LBSO shows a WHR below 1. A WHR close to or above 1 forewarns of clinical complications such as atherosclerosis, heart strokes, and infarcts. The Swedish school categorized obesity in abdominal and gluteofemoral types (Fig. 7) [31a–b, 201, 204]. The former is more prone to metabolic complications (diabetes, hypertension, heart strokes), but it is easier to treat than the latter.

The NHANES survey designed a classification based on the relationship between the BMI (body mass index) and the sum of skinfold thickness (166a–b). Thus, individuals may be classified as obese–overweight, obese–lean, overweight not obese, and lean not obese. The incidence of hypertension and hypercholesterolemia was higher in the obese-not-overweight group.

Recently, the National Institutes of Health proposed a major breakthrough on this subject. The panel concluded that a treatment for obesity was advisable even in discretely overweight patients, provided that a family history of obesity, obesity-related diseases, or personal antecedents of obesity-related diseases was present [235]. Consequently, obesity was declared a disease. Being overweight was not the single diagnostic tool used to characterize the disorder [231, 235].

“Not by Food Alone”

The overall state of obesity treatment remains a disappointing subject [22, 34, 58, 83, 84, 121, 123, 129, 163, 184, 212, 239, 292, 300]. Notwithstanding the

social pressures to keep pounds off, statistics show success in the opposite direction [1, 53, 191, 235]. Interest in the disease and research on the topic are relatively new. Until the early 1940s, the adipose tissue was a neglected subject [119], and obese patients were generally blamed for gluttony, cheating, lack of will power, and greed [123, 127, 173, 184]. Many students of obesity adhered to the nihilistic attitude that obesity is caused simply by overeating, and that it can be cured only by undereating. Despite the patients' efforts, however, for many the disease remained “incurable” [121].

Fortunately, not everyone shared this gloomy opinion of the disease. A group of researchers felt obesity might be characterized by a basic disorder of energy metabolism. Direct and indirect data contributed to the researcher's conclusions.

Indirect Data

Neumann [232] conducted a study on himself. During a prolonged control period he varied his daily food intake significantly. His weight, however, remained stable. He concluded that somehow his body managed to get rid of the surplus caloric intake.

Similar conclusions were advanced by Gulick [138] and Passmore [244]. The term “luxusconsumption” was coined to describe these clinical observations. The next step in the research was to investigate the mechanisms whereby the organism maintained a relative constancy in body weight. Miller and Mumford [222] proposed that the extra ingested calories were dissipated by heat loss during exercise, a conclusion not unanimously agreed to by other investigators [48]. Despite contradictory evidence, it soon became apparent that there was no direct relationship between daily food intake and body weight.

Sims published a classic report on this topic. In his study, normal healthy individuals fed with a high caloric diet (up to 4000 kcal/day) maintained a fairly stable weight during the test period. In those cases where weight was increased, normalization was attained by restoring subjects to a normal daily food intake. Sims concluded: “A primary disturbance of the mechanisms which monitor energy balance of the body, and which regulate food intake, could secondarily lead to metabolic and endocrine changes; these in turn could contribute to perpetuate obesity [280, 281].” Interestingly, not all the volunteers for the study showed the same response to a hypercaloric diet.

Edholm [89], after a series of clinical experiments measuring caloric intake and energy consumption in soldiers, concluded that there were no significant




Fig. 8. Possible “wasteful” or “futile cycles” in lipid metabolism. Letter “A” points to the diversion of carbohydrates into the fatty acid synthesis cycle; letter “B” to the hydrolysis–esterification cycle. Both metabolic pathways are less conservative from the bioenergetic viewpoint

correlations between body weight and daily food consumption.

Direct Data

Direct evidence from studies of obese patients were reported by several authors. Miller [223] demonstrated that under well-controlled conditions, a percentage of dieting obese patients failed to lose weight when compared with their counterparts. Since the study was performed on an in-patient basis, the failures could not be ascribed to a poor adherence to the diet. The reasons why these obese individuals were resistant to change remained unexplained.

Different reports reached the same conclusions: Obese subjects did not always overeat in the expected quantities. Some of them were, in fact, eating the same amount or less than their lean counterparts [17, 44, 170, 171a–b, 246, 293].

Theories on Obesity Genesis

Several theories have been proposed to explain the process whereby obese individuals maintain an abnormal high regulation of body weight. Keesey et al. suggested the concept of a “set point” for body weight regulation [179–181]. Consistent with his reports, the organism regulates a stable body weight by means of a precise system tuned to a fixed “set point”. Keesey et al. proposed that obese patients possess an abnormally elevated set point. Thus, their organisms adjust energy metabolism to an increased level of body weight.

Some data contend that obese patients may show an altered activity of “futile” metabolic cycles [167, 298]. This implies the continual cycling of substrates through a series of synthetic and degradative reactions which have the same initial and final energy status. This type of reaction is energy demanding and results in loss of the energetic efficiency of the system, dissipating a great amount of heat. The following “futile cycles” have been suggested bear some relevance in obesity (Fig. 8): (a) the fatty acid synthesis–oxidation cycle and (b) the triglyceride hydrolysis–reesterification cycle. Both cycles involve the HSL (hormone-sensitive lipase). This is activated by adrenaline, thus explaining their lipolytic and probably their calorogenic affects on adipose tissue [298].

The issue of whether obese patients show an increased metabolic efficiency, or a thermogenic defect, still remains an open question [23, 88, 117, 142, 176, 277, 283]. More recently, it has been suggested that obese patients may show an impairment of FFA (free fatty acid) mobilization from adipose tissue [210].

Conclusions

Obviously much work remains to be done in this fascinating field of energy metabolism. However, from our perspective the following conclusions may be drawn:

1. Nonobese individuals preserve a stable body weight regardless of wide fluctuations in daily caloric intake [66, 70].

2. Similar regulatory mechanisms seem to operate in obese patients. Unfortunately for them, this regulatory system maintains an increased level of body weight despite periods of forced dieting [206].

With respect to the processes involved in this bioenergetic cycle, Hirsch has elegantly concluded: “The persistence of obesity in the face of well-publicized information on the health hazard of obesity . . . suggests to me that there is a more subtle problem of obesity that many of us have been lead to believe” [151].

Obesity: A Multifactor Disorder

Evidence suggests that obesity is a multifactor disorder. A huge body of data concludes that genetics [9, 39, 41, 52, 54, 125, 167, 297, 304, 329], the environment [24, 43, 81, 82, 87, 156, 193, 245, 261, 301a], psychological traits [75, 122, 252, 258], socioeconomic level [5, 12, 259, 301a], development [90, 172, 182, 183, 205, 328], and a CNS (central nervous system) disturbance [7, 21, 49, 116, 175, 197, 253] contribute to the genesis or the maintenance of the disorder. Thus “nature” and “nurture”, in variable

Table 1A. Site differences in subcutaneous fat metabolism after one week of therapeutic fasting of obese subjects (from [11])

Metabolic event	Abdominal fat	Femoral fat
Basal metabolism	Profound changes	Less profound changes
Catecholamine action	No change	Increased α -adrenergic effect Inhibition at post receptor level
Antilipolytic effect of insulin	No change	Increased sensitivity
Fat cell size	Decrease	No change

Table 1B. Site differences in subcutaneous fat metabolism after one week of therapeutic fasting of obese subjects (from [11])

Fat cell size	F > A ^a
Basal lipolysis rate	F < A
Basal lipoprotein lipase activity	F > A
Insulin action	F > A
Catecholamine action	F < A

^a F = femoral fat cells; A = abdominal fat cells

proportions, are equally important in the consideration of obesity [17, 37, 51a, 56, 77, 135, 152, 168, 339].

Adipose Tissue

Heterogeneity and Multiple Physiological Aspects of the Adipose Tissue

The adipose tissue is not a uniform mass randomly distributed throughout the human body. Depending on topographic localization, adipocytes possess different sensitivities to hormones, enzymes, drugs, and fasting periods [10, 11, 38, 91, 177, 203, 287, 288, 306, 315]. The processes of lipolysis and lipogenesis in adipocytes are subject to the action of several hormones and drugs (for review see [78]). It has been observed that during fasting catecholamines inhibit femoral fat lipolysis in women [10, 11]. According to Arner [10, 11] these findings may be explained by the recent observation that the β -adrenergic receptor number is decreased in femoral fat pads during therapeutic fasting [10, 11, 240]. Insulin binding to adipocytes is modified in different fat deposits during therapeutic fasting (Tables 1a and 1b) [91]. On the other hand, some evidence concludes that the adipose tissue is quite an active mass as far as the metabolism of FFA [78], steroid hormones [97a,b], and amino acids [310] is concerned.

Lipoprotein Lipase (LPL)

Lipoprotein lipase (LPL) is an enzyme that hydrolyzes plasmatic VLDL (very-low-density lipoproteins) and chylomichrons, thus releasing FFA from the intravascular lumen. The adipocyte takes up these FFA and reesterifies them to triglycerides (TG) in the interior of the fat cell (Fig. 9). Several reports suggest that a high LPL adipose tissue activity, as seen in some obese subjects, predisposes them to increased fat storage [131, 238, 257, 274].

LPL activity was found to be higher in the femoral than in abdominal regions in women, except during lactation. During lactation, however, LPL activity is decreased in women's femoral fat pads. These findings suggest that femoral adipose tissue possesses a particular metabolic specialization during lactation [254].

Steroid Hormones

There exists an extremely large pool of steroid hormones in adipose tissue, several times that observed in plasma [97a,b]. Consequently, the adipose mass may be an important variable of steroid hormone metabolism in humans.

Adipocyte Regeneration in Adult Individuals?

Earlier reports suggested that the adipose cell does not multiply in adults [29, 30, 47, 149, 268, 269]. Based on this preliminary data, it was speculated that SAL could be the appropriate tool for the treatment of obesity [162]. Nevertheless, this enthusiastic surgical approach to a longstanding problem of human metabolism soon was over shadowed by a series of reports that concluded that the adipocyte may, indeed, multiply in adult individuals. Evidence of this came from experiments in animals and the long-term followup of obese patients.




Fig. 9. The mechanism of action of LPL (lipoprotein lipase). The enzyme hydrolyzes VLDL (very low density lipoproteins) and Chyl. (chylomicrons) from plasma, releasing FFA (free fatty acids) in the extracellular space. The adipocyte (Ad.) uptakes these FFA and reesterifies them back to TG (triglycerides). When needed, these TG are hydrolyzed back to FFA by the HSL (hormone-sensitive lipase) and released in the circulation coupled to the albumin (Alb.) fraction.

Adipocyte Regeneration in Rodents

Roth [264] demonstrated that after a lipectomy, the remaining fat cells multiply in rats. Miller [226] showed evidence concerning a *de novo* production of adipocytes in adult rats. Faust showed that under certain conditions, specific rat adipose tissue pads may regenerate [93, 96].

Adipocyte Regeneration in Humans

Foley [105] concluded that overeating leads to recruitment of new adipose cells in moderately obese patients. Sjöström et al. suggested that the adipose cells multiply in adult subjects [282a,b]. One of his reports was a long-term followup of obese women [282a]. Kral [199a,b], in a followup of three lipectomized women, observed that one had regained the weight she had before the operation, a second patient had to keep a rigorous diet to maintain her weight, and there is no data concerning the third patient. Kral concludes: "Surgical reduction of fat mass does not seem to prevent a future weight gain." Taken together, these data suggest that the total adipose mass is under the control of some type of regulatory mechanism. This "homeostatic" system might compensate for eventual losses of fatty tissue through hypertrophy and/or hyperplasia from the adipocytary pool.

Regulation of the Adipose Tissue Mass

Maintenance of a fairly stable weight throughout life or the recovery of the adipose mass after surgical interventions strongly suggests that there exists a CNS (central nervous system) mechanism that controls fat deposition and release in adipose tissue

(for review see [332]). The proposal of the hypothalamic region as the regulatory organ appears plausible [209, 332]. The hypothalamus has been reported to play a regulatory role in the menstrual cycle [20, 100], cardiac frequency [227], and immunity [76]. Thus, it is reasonable to assume that body energy homeostasis is modulated in the hypothalamic region as well [251, 332] (Fig. 10). However, a major drawback to this hypothesis lies in the difficulty to extrapolate some clinical conditions as observed in humans (e.g., obesity) with the results of experiments in animals.

Part II: The hCG Method for Obesity Treatment

"There are, it may be, so many kinds of voices in the world, and none of them is without significance"

I Corinthians

Introduction

As is well known, the first protocol for the management of obesity with hCG was reported in *Lancet* [278] by the late Dr. A.T.W. Simeons. However, previous publications concluded that hCG was a useful drug for the treatment of certain clinical presentations of adolescent obesity, except Fröhlich's syndrome [65, 116].

Since 1966 this clinic has managed obese patients with the hCG method. As experience was gained by treating 12,000 obese subjects, modifications to the original protocol were introduced. Uniform results, excellent body contour after treatment, and absence of clinical complications are the main characteristics of this outstanding form of obesity therapy. The




Fig. 10. The hypothalamic region. Different hypothalamic nuclei and their relationships to pituitary gland can be seen. PRL: prolactin; LH: luteinising hormone; FSH: follicle stimulating hormone; ACTH: adrenocorticotrophic hormone; TSH: thyroid stimulating hormone; GH: growth hormone. Hormones from the posterior part of pituitary: Vp: vasopressine; Oxy: oxitocyne

procedure was accepted [80] until the mid-1970s when, for several reasons, it fell from credibility:

1. An excessive proliferation of the so-called "fat clinics." These institutions injected hCG under totally uncontrolled conditions [19]. Unproper management of the hCG protocol resulted in an increased rate of clinical complications [86].

2. An overestimation of the real therapeutic possibilities of hCG. Publicity lead the people to believe that hCG was the "magic wand" that would cure their disease.

3. A series of clinical tests, which nearly all [61, 74, 108, 130, 140, 224, 276, 289, 294, 337] but one well-controlled one [14] concluded that the method was of no use for obesity treatment.

We have postulated elsewhere [320a–325] that hCG is *not* the magic solution to cure obesity. A daily injection of hCG gives optimum results *only when used in a rational weight reduction program. Therefore, strict observation to the complete protocol is mandatory.*

A Hypothetical Framework

This clinic is engaged in a study program on the subject. We have developed a working hypothesis based on the results of our clinical experience, on

recent evidence from the field of obesity research, and on some speculative hypotheses. The latter were introduced when experimental data were not available. The model is incomplete and much work remains to be done to test the validity of these hypotheses.

A Working Hypothesis in Obesity Therapy. The basic postulates of our model are (1) obesity is not the same as being overweight, (2) obesity has physical signs, (3) human obesity might be characterized by a hypothalamic disorder, (4) the hCG method comprises pharmacologic, behavior modification, and dietetic aspects. The pharmacologic aspects are (a) hCG is lipolytic *in vivo*, (b) hCG may act at the hypothalamic level, (c) hCG affects mood behavior.

1. *Obesity is not the same as being overweight.* As we have seen before, recent data indicates that obesity is a different clinical entity than being overweight. Several lines of evidence contribute to this hypothesis:

Gynoid type of obesity is preserved from the clinical complications appearing in android obesity. When compared with similar weights, the latter appears more "malignant" than the former [313, 316].

Recent laboratory tests have reported abnormalities suggesting metabolic complications of obesity in normal or near-normal weight subjects

[267]. Therefore, current classifications of obesity in terms of body weight may not correlate with clinical severity of the disorder.

According to the NHANES survey conclusions, incidence of hypertension is higher in obese but not overweight individuals [166a,b].

The National Institutes of Health consensus panel concluded that appropriate timing to treat obesity may depend on clinical variables other than height and weight [235].

Taken together, these data indicate that obesity and being overweight are not interchangeable terms: the former may be a clinical disease, whereas the latter could be a sign of disease, not a disease itself [50]. Should this be true, then the assessment of obese subjects should include variables other than height and weight alone.

2. *Does obesity have physical signs?* As far as we know, it was Dr. A.T.W. Simeons who described for the first time physical signs that he considered typical of obesity [279]: (1) one or two folds of skin around both sides of the back or the chest, (2) the presence of a fat pad on the nape of the neck in an otherwise moderately obese patient, (3) a noticeable valgum of the knees, (4) a fat pad inside the knees. These physical signs could be “clinical markers” used to separate obese individuals from those who are simply overweight. Obese patients should be treated with a more energetic weight reduction program because they show a higher incidence of clinical complications.

3. *Obesity might be characterized by a hypothalamic disorder.* Notwithstanding recent data that suggest that the adipocyte might be the main cause of obesity [94, 95, 132, 262], there is much evidence that the total body fat mass is regulated by a central nervous system modulatory system [209, 214, 332]. Therefore, despite genetic influences may predispose adipose cells to accumulate lipids [41, 79, 132, 147], the overall activity of fat deposition and release must depend on an integratory circuit, which should control the metabolic activity of diverse fat cells all over the organism.

A well-studied topic is the relationship between hypothalamic experimental lesions and the development of obesity in rats. In 1939, Hetherington and Ranson [143, 144] reported that small electrolytic lesions in the VMN (ventral hypothalamus) resulted in hyperphagia and obesity. Though the first publications focused on the metabolic and endocrine disorders accompanying hypothalamic lesions, later on several reports insisted that a basic modification in eating behavior (hyperphagia) heralded the onset of metabolic abnormalities (hyperinsulinemia) [8a,b, 185, 286, 295, 296]. However, recent investigations suggest this interpretation may be incorrect. A current formulation for these syndromes proposes that neurally mediated hyperinsulinemia is

the primary factor contributing to excessive fat accumulation [164, 165]. This concept is not shared by all investigators [134, 295, 296].

Despite the controversy on the subject, it is generally agreed the hypothalamus somehow plays a regulatory role in the mechanism of energy metabolism regulation [67, 112, 120, 158, 169, 209, 214, 215, 225, 243, 251, 272, 332]. Nevertheless, a major problem lies in the extrapolation of the results obtained in animal experiment to the clinical condition of obesity as observed in humans. Except for a handful of cases [49, 64] no demonstrable hypothalamic lesions have been reported in common obesities. Thus, it appears that experimental animal models of obesity are of limited value when considering human obesity (for a review on experimental and genetic models of animal obesity see [51b, 101]).

A reasonable alternative to this problem may be that human obesity might be characterized by a subtle hypothalamic disorder, still not accessible to current diagnostic methods [112, 272]. Indirect evidence that supports this hypothesis is seen in several experiences in humans. Amatruda et al. [7] demonstrated that a group of obese males showed an abnormal response to 100 μ g of GnRH (gonadotropin releasing hormone). Jung et al. [174] concluded that women with familial obesity have a hypothalamic function disorder which was not totally corrected after weight loss. Kopelman et al. [195, 196], after studying the prolactin (PRL) response to insulin-induced hypoglycemia, concluded that hypothalamic function is disturbed in massive obesity. The causes for this regulatory disorder are presently unknown.

A Hypothalamic Opioid Disorder in Human Obesity?

Recent data from the opioid research field opened a new perspective in the consideration of human obesity: Obesity might result from an opioid regulatory derangement in the diencephalic region [220]. Several data suggest that CNS opioids regulate energy metabolism [192, 216–218, 335] and ingestion of nutrients [126, 178, 207, 228–230, 270, 285, 335]. One of the best studied neuropeptides is β -endorphin. It has been suggested that this opioid acts upon the mechanism that elicits eating through a “food-rewarding” system. This cycle might function as follows: Food ingestion may increase CNS opioid levels [216]. This creates a “self-gratifying” sensation [62]. Therefore, obese subjects should be compelled to elevate their food intake to maintain an elevated CNS opioid concentration [62].

From this perspective, gluttony observed in obese patients could be explained on a biochemical basis: Addiction to food would be a recognizable

CNS opioid disorder. Following this line of reasoning, food restriction in obese subjects would decrease the content of CNS endorphins, creating a "withdrawal syndrome" similar to that observed in drug addicts. This hypothesis finds partial support in the Gambert et al. report [115] that concludes that fasting decreases the content of hypothalamic β -endorphin in rats.

We hypothesize that modification of the content of hypothalamic opioids may be related to energy metabolism as follows:

1. Hypothalamic neuropeptide hypersecretion in obese patients may create a dependence on food because food intake would increase CNS opioid concentration [and thus self-gratification]. In this case, obesity would be maintained by an elevated energy input. A persistent high food intake level could lead to metabolic changes which may in turn perpetuate obesity [280, 281].

2. The hypothalamus might be part of the diffuse neuroendocrine system, as proposed by Margules [217, 218]. He suggested that opioids are the neuro-modulators of this system. Any stressful situation—a diet, for example—could disrupt the homeostasis of the system. In the case of a diet, the period of decreased energy input would be compensated by physiological adjustments in energy metabolism. This counterregulatory phenomenon could result in the maintenance of the body weight "set-point."

Finally, some evidence seems to suggest that the diencephalic region plays a regulatory function in the metabolism of fat deposition and release. Research on hypothalamic neuropeptides may shed new light on the interpretation of obesity. Subtle modification of the diencephalic opioid concentration may be the cause or an indication of an underlying neuromodulatory disturbance. This would, in turn, initiate the metabolic changes that lead to obesity.

4. Multiple Aspects of the hCG Protocol

Pharmacologic Aspect: hCG is lipolytic in vivo. According to Simeons [278], obesity was characterized by the presence of an "abnormal" adipose tissue. These fat pads were localized in specific body areas. Simeons suggested that hCG showed an affinity for these fat masses. As far as we know, there are no reports proposing that hCG mobilizes this "abnormal" fat. However, some data demonstrate that hCG can mobilize lipids from adipose tissue.

Fleigelman [104] concluded that the administration of hCG in rats decreased the activity of α -glycerophosphate dehydrogenase and glucose-6-phosphate dehydrogenase from the liver and adipose tissue. This could mean a diminished lipogenic activity in both tissues under hCG (Fig. 11).




Fig. 11. The activity of two enzymes from rat adipose tissue before (A) and after (B) hCG administration. AGPD: soluble α -glycerophosphate dehydrogenase; G6PD: glucose-6-phosphate dehydrogenase. (All enzymatic activities are expressed as micrograms formazan/ μ g nitrogen) (Drawn from [104])

Yanagihara [334] reported that hCG accelerates "not only mobilization of fat from fat deposits, but also its utilization in peripheral tissues. hCG increased the metabolism of injected fat emulsions, suggesting not only the acceleration of not only oxidation of fat, but increased ketone production in the liver and its utilization in peripheral tissues." Romer [260] reported that hCG intensifies the metabolism of rat brown adipose tissue.

Administration of hCG in humans appears to increase the release of free fatty acids that varies with the age of the subjects. Melichar et al. [221] demonstrated that hCG causes a marked FFA release in newborn infants. In adults, a single injection of hCG stimulated the release of FFA by $P > 0.05$ when compared with placebo-treated individuals. This lipolytic action of hCG appears to be mediated. Tell [309] reported that adipocytes do not possess receptors for hCG. Therefore, the lipolytic action of hCG is mediated through an organ or system, which may release a lipid-mobilizing substance in response to hCG stimulation.

Alternatively, chCG (crude, commercial hCG) may exert an *in vitro* lipolytic activity: commercial preparations of hCG contains β -endorphin [139], an opioid peptide with a suggested *in vitro* lipolytic activity [255].

hCG might act at hypothalamic level. At this point, it seems relevant to discuss some data regarding hCG. hCG is a glycoprotein hormone, normally secreted by trophoblastic cells of the placenta during pregnancy [275]. It consists of two dissimilar, separately but coordinately translated chains called the alpha and beta subunits [27, 59, 102, 249, 317, 318]. The three pituitary hormones LH (luteinizing hormone), FSH (follicle stimulating hormone), and TSH (thyroid stimulating hormone) are closely related to hCG in that all four are glycosylated and have a dimeric structure comprising Alpha and Beta chains as well. The amino acid sequences of the alpha chain of all four human glycoprotein hormones are nearly identical. The amino acid sequences of the beta subunits differ because of the unique immunological and biological activities of each glycoprotein hormone [263]. β -hCG contains a carboxylic residue of 30 amino acids that are characteristic of hCG [25–27].

Its name, human chorionic gonadotropin originated when it was found that hCG matured the infantile sex glands (gonadotropin) and that it was secreted by the placenta (chorionic) [13, 338]. Recent data suggest, however, that both terms can be quite misleading: normal human tissues [45, 305, 336], plasma from nonpregnant subjects [40, 242], trophoblastic and nontrophoblastic tumors [55, 68, 71, 153, 236, 265, 266, 291, 317], bacteria [3, 16, 213, 219, 284], and plants [85, 109, 110] express hCG or a hCG-like material (for review see [157]). Recently, it has been suggested that this hCG-like material may act as a local growth modulatory factor (D. Belluscio, unpublished).

As far as the scope of this article is concerned, we see that the hypothalamic region is a target organ for the extragonadal actions of hCG. Yaginuma [333] showed that in rats peripherally injected ^{125}I -hCG crosses the blood–brain barrier and accumulates in the hypothalamic region. Hirono [148] reported that hCG has a direct effect on hypothalamic median eminence (ME), inhibiting the synthesis and release of FSH and the release of LH from the anterior pituitary through the hypothalamus. Board [36] demonstrated that hCG administration increases the secretion of the growth hormone in humans. hGH (human growth hormone) may perform lipolytic [98] and calorogenic [46] functions in humans. Thus, hCG could stimulate hGH secretion. This would, in turn, stimulate lipolysis from adipose tissue. Alternatively, and from a purely speculative viewpoint, hCG could stimulate, through the hypothalamus, the secretion of a pituitary lipid-mobilizing factor [57].

hCG and mood behavior. A most intriguing clinical aspect of the hCG program is the sense of well-being observed in treated patients [14, 278, 279, 319–325]. However, these findings were refuted by several publications [130, 224, 294, 337]. Neverthe-

less, recent data may shed some light on the subject: Hashimoto and Sawai reported that commercial preparations of hCG contain β -endorphin [139], a neuropeptide related to changes in mood behavior [136, 271]. Pure hCG contains β -endorphin as well [2]. Consequently, we hypothesized that the content of β -endorphin in hCG might be responsible for the slight “euphoria” observed in our patients. This opioid might act in the hypothalamic region, an area of major synthesis of β -endorphin [113, 133, 136, 198, 271]. But a major drawback to this supposition lies in the fact that except for a few reports [35, 63, 192], several studies conclude that peripherally injected β -endorphin does not cross the blood–brain barrier, or, if it does, it is either taken up by the brain or broken down with extreme rapidity [137, 154, 200, 208]. Only direct administration to the central nervous system seems to show clinical effects [248].

It occurred to us, from a pure hypothetical viewpoint, that hCG might be the “carrier” for β -endorphin into the brain, delaying its catabolism and facilitating its penetration into the brain: hCG crosses the CNS blood–brain barrier [18], and it accumulates in the hypothalamus [333]. Extremely low concentrations of the complex hCG/ β -endorphin at the hypothalamic level should be sufficient to exert a therapeutic effect: β -endorphin is one of the most potent of the tested neuropeptides [136]. Alternatively, β -endorphin could enter the brain at the spinal cord level [118].

The complex hCG/ β -endorphin may act in obese patients as follows: (1) The hypothalamic content of β -endorphin decreases during starvation [115]. If the same observation was seen in humans, then exogenous β -endorphin may prevent the withdrawal syndrome that accompanies a dieting period. (2) It could stimulate the secretion of the hypothalamic GHRH (growth hormone releasing hormone) factor and hence lipolysis [98].

Since the above are speculations, they should be read with caution: much work remains to be done to test the validity of these hypotheses.

Behavior Modification Aspect. After Stuart’s report [299], data on the utility of a behavior modification program for obesity treatment became available [99, 301b, 302, 303, 327, 330, 331]. The idea behind these programs is that the primary behavior to be changed is eating, and a number of exercises are designed to slow the rate of eating. Former behavioral programs based on only behavior modification had little success [106, 330]. Recently, however, satisfactory long-term results have been reported with a combination of behavior modification and the administration of a very low calorie diet [32, 33, 211].

In our opinion, the protocol hCG contains behav-

Table 2. A comparison between the basic behavior modification techniques comprised in the hCG protocol (**left**) and those from a current behavior modification program (**right**)

(A) Daily visits to the doctor	(A,B) Reinforcement of prescribed behaviors
(B) Daily weighing of the patient	
(C) Extreme sensitivity of the method to daily dietary errors	(C) Self-monitoring of the patients
(D) Modification of daily eating habits	(D) Development of techniques to control the act of eating
(E) A programmed maintenance period	(E) Maintenance period after treatment

ior modification procedures that are similar to the basic guidelines of a standard behavior modification protocol (Table 2).

Dietetic Aspect. Diet plays a specific role in obesity therapy: It decreases energy input thus stimulating energy consumption from fat deposits. No study that we know of has reported complications with the 500-kcal diet. Recently it has been shown conclusively that the use of the very-low-calorie diet for managing of obese patients is safe [114, 155, 190, 237, 290].

Results

First we want to ask: Does a new classification of obesity require a new clinical test? In our opinion, the value of a standard double-blind test to evaluate the hCG program seems questionable. There is no doubt that a 500-kcal diet will render an acceptable weight loss in patients who receive a daily injection of hCG, a placebo, or simply dietary advice [150, 278]. On the other hand, if obesity and being overweight are medical terms that define different clinical conditions, hCG should be tested against a placebo only in obese patients [278, 279]. Such a clinical study has never been done before and would require the close cooperation between a research laboratory and a department of internists. The latter should be fully acquainted with the minimal details of the hCG complete protocol. The research lab should be willing to initiate a research program on this poorly investigated relationship between hCG and obesity.

The following results are from our clinical experience. We prepared a random selection of 450 patients treated with the hCG method between 1971 and 1979. Results can be seen in Tables 3a and 3b. It became clear that weight loss under the hCG protocol is most substantial when compared with standard weight reduction programs. Figures 12–17 show some of our obtained results.

At the total dose indicated for a complete course of treatment with hCG (5000 IU), no complications have been reported. Gonadal hyperstimulation syn-

drome [15] and acute Meigs syndrome [111] are always related to a higher dose of hCG (20,000 IU or more), generally used in combination with hMG (human menopausal gonadotropin) [233, 307]. Minor complications have been reported: loss of telogen effluvium hair [202, 311] observed in patients subjected to a dieting period and pain at the injection site of a commercially prepared hCG, but not with a different one [141, 234].

In our experience the following minor complications were observed: (1) menstrual cycles disturbances in 0.1% of patients. Several of our obese patients who presented amenorrheic disorders prior to treatment reverted to normal cycles when weight was decreased; (2) hair loss in less than 0.01% of the treated subjects. The hair was of the Telogen effluvium (mature hair) type. Normal regrowth was observed after treatment in all cases. There were no cases of permanent alopecia reported in well over 12,000 treated subject.

Conclusions

The advent of SAL has dramatically increased the number of obese patients coming to our consultation offices. Therefore, a cooperation with a physician who specializes in obesity is of utmost importance. This team work will help in the proper selection of patients and to decide whether a medical weight reduction program should be performed in the first place.

Obesity is a multifaceted disorder. Present classifications include the assessment of height, weight, adipose tissue distribution, and familial antecedents of obesity or obesity-related diseases. Current decisions on the appropriate timing of obesity treatment are based on a careful analysis of the variables listed earlier. Patients who are five or ten pounds overweight should be treated with a weight reduction program when personal or familial antecedents advise it.

The adipose tissue reacts differently to hormones and drugs, depending its topographical localization. Conspicuous body areas seem to be more resistant to fasting because of the particular metabolic char-




Fig. 12. A 45-year-old patient before (A) and after (B) a weight loss of 13.5 kg in a 35 day course with the hCG program. Note absence of skin sagging despite the significant weight reduction




Fig. 13. Harmonious 12 kg weight loss in a 39-year-old patient treated with our protocol (40 days). Physical signs characteristic to obesity have disappeared (A) before; (B) after




Fig. 14. A 30-year-old male before (A) and after (B) a weight loss of 17.3 kg, managed with the hCG method. It can be noticed the net improvement of his abdominal type of obesity




Fig. 15. Obese 51-year-old patient before (A) and after (B) a weight reduction of 16.2 kg in the course of a hCG treatment (42 days). Observe the disappearance of striae cutanea from the lower abdomen




Fig. 16. Obese patient before (A) and after (B) a weight loss of 12.4 kg after a course of 40 days of treatment with our hCG protocol. Symmetric body fat reduction. Minimal sagginess of skin




Fig. 17. This photograph shows that proper aesthetic results can be obtained with the hCG method without any surgical procedure: arm from an obese patient before (A) and after (B) the hCG treatment

acteristics of regional adipocytes. It seems that some cases of "resistant" obesity might be explained by the decrease of the release of free fatty acid from adipose tissue, or a relative decrease in the number of beta-receptors from adipose tissue during therapeutic fasting. This relative decrease in beta-receptor number may favor the alpha action (accumulation of lipids) of hormones.

Individuals tend to maintain a fairly stable weight throughout their life. For the obese, this "set point" of body weight regulation appears abnormally elevated. This hypothesis indirectly proposes that there exist a mechanism that controls fat deposition and release. Some evidence points to the hypothalamic region as the control organ.

Counterregulatory mechanisms tend to compensate for the loss of fat mass. This compensatory growth may occur in body areas where adipocyte hypertrophy and/or hyperplasia could result in increased morbidity. On the other hand, regrowth of adipose tissue in lipectomized areas may result in the recurrence of both obesity and body contour deformity. Thus, surgical intervention on adipose tissue (SAL or lipectomies) is not advised as the method of choice for obesity therapy. Neverthe-

less, SAL has a definite place in body contour surgery for the management of small, localized fat accumulations.

The hCG protocol is a safe, appropriate approach to obesity. It combines pharmacological, behavior modification, and dietetic aspects. When properly managed, it results in a rapid weight loss and excellent body contour. Clinical complications and unfavorable results are related to hazardous modifications of the original protocol.

There is some evidence that suggests that hCG possesses lipolytic activity. Therefore, the basis of use of hCG for obesity treatment might be biochemical. Because hCG does not mobilize lipids *in vitro*, the hypothalamic region might be the intermediate organ in hCG lipolytic action. On the other hand, hCG stimulates hGH secretion. Thus, it was hypothesized that hGH might be the lipolytic hormone secreted to hCG stimulation.

Commercial preparations of hCG contain β -endorphin, and opioid peptide that may affect mood behavior. We speculated that this neuropeptide may be responsible for the sense of well-being observed in our hCG-treated patients.

Since it has been reported that β -endorphin does not cross the blood-brain barrier, it was suggested that hCG might act as a "carrier" for β -endorphin in the brain. Alternatively, β -endorphin may account for an *in vitro* lipolytic activity.

The hCG method comprises a behavior modification program that helps to a better handle obese patients. There is some correlation between the behavioral program included in the hCG protocol and a current behavior modification program for obesity treatment.

The 500-kcal diet as prescribed in the original method proved to be safe and effective.

Obesity is a widespread condition afflicting millions of individuals all over the world. It is a slow killer disease, causing disability, morbidity, and diminution of the quality of life.

Table 3A. Randomized study of 450 patients treated between 1977 and 1979 in our clinic with the hCG protocol

Total patients:	450
Females:	351
Males:	99
Age: females:	15–71 years
males:	16–75 years
Degree of overweight (%): ^a females:	54.23% (± 25.28)
males:	74.03% (± 41.06)
Average treatment (days): females:	41.24
males:	41.68

^a Degree of overweight is expressed according to the indications of the table published by the Metropolitan Life Insurance Company, 1959

Table 3B. Randomized study of 450 patients treated between 1977 and 1979 in our clinic with the hCG protocol

	Before	After	Reduction
<i>Females</i>			
Weight (kg)	81.60(± 14.25)	70.61(± 10.04)	10.99
Circumference (cm)			
Breast	105.23	98.10	7.13
Waist	89.40	79.10	10.30
Hip	111.64	101.54	10.10
<i>Males</i>			
Weight (kg)	101.60(± 16.3)	88.46(± 8.04)	13.13
Circumference (cm)			
Waist	107.72	97.05	10.67
Hip	108.97	98.57	10.40

The hCG method of treatment might be a reasonable therapeutic alternative aimed at offering relief to a longstanding unresolved problem of human metabolism.

References

1. Abraham S, Johnson CL: Prevalence of severe obesity in adults in the United States. *Am J Clin Nutr* **33**:364–369, 1980
2. Acevedo HF; Personal communication, October 1985
3. Acevedo HF, Koide SS, Slifkin M, Maruo T, Campbell-Acevedo EA: Choriogonadotropin-like antigen in a strain of *Staphylococcus faecalis* and a strain of *Staphylococcus simulans*: detection, identification and characterization, *Infect Immun* **31**(1): 487–494, 1981
4. Adler J et al: New bodies for sale. *Newsweek Int Mag* May 27, 1985, pp 38–41
5. Akesode FA, Ajibode HA: Prevalence of obesity among Nigerian school children, *Soc Sci med* **17**(2): 107–111, 1983
6. Albrink MJ: Chorionic gonadotropin and obesity? *Am J Clin Nutr* **22**(6):681–685, 1969
7. Amatruda JM, Hochstein M, Hsu TH, Lockwood DH: Hypothalamic and pituitary dysfunction in obese males. *Int J Obes* **6**(2):183–189, 1982
- 8a. Anand BK, Brobeck JR: Localization of a "feeding center" in the hypothalamus of the rat. *Proc Soc Exp Biol Med* **77**:323–324, 1951
- 8b. Anand BK, Brobeck JR: Hypothalamic control of food intake in rats and cats. *Yale J Biol Med* **24**: 123–140, 1951
9. Apfelbaum M, Fumeron F, Dunica S, Magnet M, Brigant L, Boulange A, Hors J: Genetic approach to family obesity. Study of HLA antigens in 10 families and 86 unrelated obese subjects. *Biomedicine* **33**(4):98–100, 1980
10. Arner P, Engfeldt P, Lithell H: Site differences in the basal metabolism of subcutaneous fat in obese women. *J Clin Endocrinol Metab* **53**:948–952, 1981
11. Arner P: Site differences in human subcutaneous adipose tissue metabolism in obesity. *Aesth Plast Surg* **8**:13–17, 1984
12. Arteaga H, Dos Santos JE, Dutra de Oliveira JE: Obesity among school children of different socioeconomic levels in a developing country. *Int J Obes* **6**(3):291–297, 1982
13. Ascheim S, Zondek B: Die Schwangerschaftsdiagnose aus dem Harn durch Nachweis der Hypophyse vor dem Lappenhormon. *Klin Wschr* **7**:1404–1411, 1928
14. Asher WL, Harper HW: Effect of human chorionic gonadotropin on weight loss, hunger and feeling of well-being. *Am J Clin Nutr* **26**:211–218, 1973
15. Aubert L: Développement aigu d'un kyste de l'ovaire et grossesses quintuples chez une femme ayant reçu successivement des gonadotropins seriques et chorioniques. *Ann Endocrinol (Paris)* **21**:176–182, 1960.
16. Backus BT, Affront LF: Tumor-associated bacteria capable of producing a human-chorionic gonadotropin-like substance. *Infect Immun* **32**:1211–1215, 1981
17. Baecke JA, Burema J, Frijters JE, Hautvast JGAJ, Van der Wiel EF, Wetzels WA: Obesity in young Dutch adults. I: Socio-demographic variables and body mass index. *Int J Obes* **7**(1):1–12, 1983
18. Bagshawe KD, Orr AH, Rushwort AGJ: Relationships between concentration of hCG in plasma and cerebrospinal fluid. *Nature* **217**:950–951, 1968
19. Ballin JC, White PL: Fallacy and hazard: hCG, 500-Kcal diet and weight reduction. *J Am Med Assoc* **230**(5):693–694, 1974
20. Barnea ER, Naftolin F, Tolis G, de Cherney A: Hypothalamic amenorrhea syndromes. In: Givens E, Jr, ed, *The Hypothalamus*. Chicago: Year Book Medical Publishers, 1984, pp 147–170
21. Bauer HG: Endocrine and other clinical manifestations of hypothalamic disease. *J Clin Endocrinol Metab* **14**:13–31, 1954
22. Beck EC, Hubbard RS: A study of 63 patients before and after weight reduction. *NY State J Med* **39**: 1102–1107, 1939
23. Bessard T, Schutz Y, Jéquier E: Energy expenditure and postprandial thermogenesis in obese women before and after weight loss. *Am J Clin Nutr* **38**:680–693, 1983
24. Bindon Jr, Baker PT: Modernization, migration and obesity among Samoan adults. *Ann Hum Biol* **12**(1): 67–76, 1985
25. Birken S, Canfield RE: Isolation and amino acid sequence of COOH-terminal fragments for the β -subunit of human-chorionic gonadotropin. *J Biol Chem* **252**:5386–5391, 1978
26. Birken S, Fetherston J, Canfield RE, Boime I: The amino acid sequence of the prepeptides contained in the α and β -subunits of human choriogonadotropin. *J Biol Chem* **256**(4):1816–1823, 1981
27. Birken S: Chemistry of human choriogonadotropin. *Ann Endocrinol (Paris)* **45**:297–305, 1984
28. Birmingham L, Smith K: Human chorionic gonadotropin is of no value in the management of obesity. *Can Med Assoc J* **128**:1156–1157, 1983
29. Björntorp P, Sjöström L: Number and size of adipose tissue fat cells in relation to human metabolism is human obesity. *Metabolism* **20**:703–713, 1971
30. Björntorp P, Carlgren G, Isaakson B, Krotkiewski M, Larsson B, Sjöström L: Effect of an energy-reduced dietary regimen in relation to adipose tissue cellularity in obese women. *Am J Clin Nutr* **285**: 445–452, 1975
- 31a. Björntorp P: Adipose tissue in obesity (Willendorf Lecture). In: Hirsch J, Van Itallie TB, eds, *Recent Advances in Obesity Research (IV)*. London: John Libbey, 1985, pp 163–170
- 31b. Björntorp P: Regional patterns of fat distribution. *Ann Intern Med* **103**:994–995, 1985
32. Björvell H, Rossner S: Long-term treatment of severe obesity. Four-year follow-up of results of combined behavioral modification program. *Br Med J* **291**:379–382, 1985
33. Björvell H, Rossner S: The attrition rate can be reduced in long-term behavioral treatment of obesity. *Abstr Vth Int Congr Obesity*. Jerusalem, September 14–19, 1986, p 61
34. Blondheim SH, Kaufman M, Stein M: Comparison of fasting and 800–1000 Kcal diet in obesity. *Lancet* **I**:250–252, 1965
35. Bloom F et al: Endorphins: developmental, endocrinological and behavioral actions. In: McIntyre

- G, Szelke M, eds, *Molecular Endocrinology*. London: Elsevier North-Holland Medical Press, 1979, pp 39–64
36. Board JA: Levels of plasma hGH during administration of human menopausal gonadotropin and human chorionic gonadotropin. *Obstet Gynecol* **31**(1):116–118, 1968
 37. Bogg RA: Genetic component of obesity (letter). *Lancet* **II**(7996):1205, 1976
 38. Bolinder J, Engfeldt P, Östman J, Arner P: Site differences in insulin receptor binding and insulin action in subcutaneous fat of obese females. *J Clin Endocrinol Metab* **57**(3):455–461, 1983
 39. Borjeson M: The aetiology of obesity in children. A study of 101 twin pairs. *Acta Paediatr Scand* **65**(3):279–287, 1976
 40. Borkowski A, Marquardt C: Human chorionic gonadotropin in the plasma of normal, nonpregnant subjects. *N Engl J Med* **301**:298–302, 1979
 41. Bouchard C: Inheritance of fat distribution and adipose tissue metabolism. In: Vague J, Björntorp P, Guy-Grand B, Rebuffé-Scrive M, Vague P, eds, *Metabolic complications of human obesities*, Excerpta Medica (Congress Series 682). Amsterdam: Elsevier, 1985, pp 87–96
 42. Boyer A: L'hCG dans l'obésité: non, non et non! *Med Quebec* **Juin**:81–82, 1976
 43. Bradley PJ: Is obesity an advantageous adaptation? *Int J Obes* **6**(1):43–52, 1982
 44. Braitman L, Adlin V, Stanton JL: Obesity and caloric intake: National health and nutrition examination survey of 1971–1975 (NHANES I), *J Chron Dis* **38**(9):727–732, 1985
 45. Braunstein GC, Kamdar V, Rasor J, Swaminathan N, Wade ME: Widespread distribution of a chorionic gonadotropin-like substance in normal human subjects. *J Clin Endocrinol Metab* **49**:917–925, 1979
 46. Bray GA: Calorigenic effect of human growth hormone in obesity. *Metabolism* **29**:119–122, 1969
 47. Bray GA: Measurements of subcutaneous fat cells from obese patients. *Ann Intern Med* **73**:565–569, 1970
 48. Bray GA, Whipp BJ, Koyal SN: The acute effects of food intake on energy expenditure during cycle-ergometry. *Am J Clin Nutr* **27**:254–259, 1974
 49. Bray GA, Gallagher TF: Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. *Medicine* **54**(4):301–330, 1975
 50. Bray GA: To treat or not to treat—that is the question? In: Bray GA, ed, *Recent Advances in Obesity Research (II)*. London: Newman Publishing Co., 1978, pp 248–265
 - 51a. Bray GA: Human obesity and some of its experimental counterparts. *Ann Nutr Alimen* **33**(1):17–25, 1979
 - 51b. Bray GA, York DA: Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. *Physiol Rev* **59**(3): 719–809, 1979
 52. Bray GA: The inheritance of corpulence. In: Cioffi LS, James WPT, Van Itallie TB, eds, *The Body Weight Regulatory System*. New York: Raven Press, 1981, pp 185–195
 53. Bray GA, McCall J: Dieting: The losing game. *Time* **127**(3):42–48, 1986
 54. Breckenbridge WC, Little JA, Alaupovic P, Lindgren FT, Kursis A: Abnormal triglyceride clearance secondary to familial apolipoprotein C-II deficiency. In: Angel A, Hollenberg CH, Roncari DAK, eds, *The Adipocyte and Obesity: Cellular and molecular mechanisms*. New York: Raven Press, 1983, pp 137–148
 55. Broder LE, Weintraub BD, Rosen SW: Influence of chemotherapeutic agents on chorionic gonadotropin α -subunit secretion in a human lung cancer cell line (chAGo): Discordance of secretion and cytotoxic effects. *J Natl Cancer Inst* **61**(2):349–351, 1978
 56. Brownell KD: Behavioral, psychological, and environmental predictors of obesity and success at weight reduction. *Int J Obes* **8**(5):543–550, 1984
 57. Burns TW, Hales CN, Stockell Hartree A: Observations on the lipolytic activity of human serum and pituitary fractions in vitro. *J Endocrinol* **39**:213–225, 1967
 58. Campbell CJ, Campbell IW, Innes JA, Munro JF, Needle AL: Further follow-up experience after prolonged therapeutic starvation. In: Burland W, ed, *Obesity*. London: Churchill-Livingstone, 1974, pp 281–292
 59. Canfield RE, Morgan FJ, Kammerman S, Bell JJ, Agosto GM: Studies of human chorionic gonadotropin. *Rec Prog Horm Res* **27**:121–164, 1971
 60. Cargille CM: Human chorionic gonadotropin not indicated for obesity. *J Am Med Assoc* **219**(11):1485–1486, 1972
 61. Carne S: The action of chorionic gonadotropin in the obese. *Lancet* **II**:1282–1284, 1961
 62. Carr KD, Simon EJ: The role of opioids in feeding and reward elicited by lateral hypothalamic electrical stimulation. *Life Sci* **33**:563–566, 1983
 63. Catlin DH, Gorelick DA, Gerner RH, Hui KK, Li CH: Clinical studies with human β -endorphin. In: Beers AF, Bassett EG, eds, *Polypeptide Hormones*. New York: Raven Press, 1980, pp 337–352
 64. Ceesia GG, Archer CR, Chung HD: Hyperphagia and obesity, relationship to medial hypothalamic lesions. *J Am Med Assoc* **246**(2):151–153, 1981
 65. Ceresa F: La terapia con ormone gonadotropo coriale e con tiroide delle distrofie adiposo-ipersomiche ipo-e normogenitali dell'adolescente. *CI Ter* **4**:24–40, 1953
 66. Chinn S: In: Garrow SJ, ed, *Energy Balance and Obesity*. New York: North-Holland, 1974, pp 21–23
 67. Coimbra CC, Migliorini RH: Evidence for a longitudinal pathway in the rat hypothalamus that controls free fatty acids mobilization. *Am J Physiol* **245**: E332–E357, 1983
 68. Cole, LA, Birken S, Sutphen S, Hussa RO, Pattillo R: Absence of the COOH-terminal peptide on ectopic hCG- β subunit. *Endocrinology* **110**(6):2198–2200, 1982
 69. Colon G: Liposuction: the downside (letter). *Plast Reconstr Surg* **75**(1):132–133, 1985
 70. Comstock GW, Stone RW: Changes in body weight and subcutaneous fatness related to smoking habits. *Arch Environ Hlth* **24**:271–276, 1972
 71. Couch WD: Combined effusion fluid tumour marker assay, carcinoembryonic antigen (CEA) and human chorionic gonadotropin (hCG) in the detection of malignant tumours. *Cancer* **48**:2475–2479, 1981

72. Courtiss EH: Suction lipectomy: A retrospective analysis of 100 patients. *Plast Reconstr Surg* **73**(5): 780–794, 1984
- 73a. Courtiss EH: Precise terminology for suction lipectomy. *Plast Reconstr Surg* **75**(1):132, 1985
- 73b. Courtiss EH: Suction lipectomy: complications and results by survey (discussion). *Plast Reconstr Surg* **76**(1):70–72, 1985
74. Craig LS, Ray RE, Waxler SH, Madigan H: Chorionic gonadotropin in the treatment of obese women. *Am J Clin Nutr* **12**:230–234, 1963
75. Crisp AH: Some psychiatric aspects of obesity. In: Bray GA, ed, *Recent Advances in Obesity Research (II)*. London: Newman Publishing Co., 1978, pp 336–344
76. Cross RJ, Markesbery WR, Brooks WH, Roszman TL: Hypothalamic-immune interactions. I. The acute effect of anterior hypothalamic lesions on the immune response. *Brain Res* **196**:79–87, 1970
77. Daniels JS: The pathogenesis of obesity. *Psychiat Clin N Am* **7**(2):335–347, 1984
78. Davies JJ, Souness JE: The mechanisms of hormone and drugs actions on fatty acid release from adipose tissue. *Rev Pure Appl Pharmacol Sci* **2**:1–112, 1981
79. Digy JP et al: HLA and familial obesity: evidence for a genetic origin. In: Hirsch J, Van Itallie TB, eds, *Recent Advances in Obesity Research (IV)*. London: John Libbey, 1985, pp 171–175
80. Dietz RE, LaCroix E: Roundtable: Drug therapy in obesity. Part II. *Ob Bar Med* **9**(1):15–25, 1980
81. Dietz W: Obesity in infants, children and adolescents in the United States. I. Identification, natural history and after effects. *Nutr Res* **1**:117–137, 1981
82. Dietz WH Jr, Gortmaker SL: Factors within the physical environment associated with childhood obesity. *Am J Clin Nutr* **39**(4):619–624, 1984
83. Drenick EJ: Weight reduction by prolonged fasting. In: Bray GA et al, eds, *Obesity in perspective*. Washington, DC: DEW Publ, 1975, pp 341–360
84. Drenick EJ, Johnson D: Weight reduction by fasting and semistarvation in morbid obesity: long-term follow-up. *Int J Obes* **2**:123–132, 1978
85. Duffus CM, Duffus JH, Orr AH: Inhibition of gibberellic acid biosynthesis by chorionic gonadotropin during cereal grain germination. *Experientia* **26**(12): 1296–1297, 1970.
86. Dunn CE: Human chorionic gonadotropin for weight reduction. *Am J Obstet Gynecol* **120**:855, 1974
87. Durant RH, Martin DS, Linder CW, Weston, W: The prevalence of obesity and thinness in children from a lower socioeconomic population receiving comprehensive health care. *Am J Clin Nutr* **33**(9): 2002–2007, 1980
88. Dusmet H (quoted by Jèquier E, Schutz Y): Does a defect in energy metabolism contribute to human obesity? In: Hirsch J, Van Itallie TB, eds, *Recent Advances in Obesity Research (IV)*. London: John Libbey, 1985, pp 76–80
89. Edholm OG: Energy expenditure and food intake. In: *Energy balance in man*. Apfelbaum M, ed, Paris: Masson et Cie, 1973, pp 51–60
90. Edwards LE, Dickes WF, Alton IR, Hakanson EY: Pregnancy in the massively obese: course, outcome and obesity prognosis of the infant. *Am J Obstet Gynecol* **131**(5):479–483, 1978
91. Engfeldt P, Bolinder J, Ostman J, Arner P: Effects of fasting on insulin receptor binding and insulin action in different human subcutaneous fat depots. *J Clin Endocrinol Metab* **60**(5):868–873, 1985
92. Evans DJ, Kissebah AH, Vydellingum N, Murray R, Hartz AJ, Kalkhoff RK, Adams PW: Relation of body fat distribution to metabolic complications of obesity. *J Clin Endocrinol Metab* **54**:254–260, 1982
93. Faust IM, Johnson P, Hirsch J: Adipose tissue regeneration following lipectomy. *Science* **197**:391–393, 1977
94. Faust IM, Miller WH: Hyperplastic growth of adipose tissue in obesity. In: Angel A, Hollenberg CH, Roncari DAK, eds, *The adipocyte and Obesity. Cellular and Molecular mechanisms*. New York: Raven Press, 1983, pp 41–51
95. Faust IM: Role of the fat cell in energy balance physiology. In: Stunkard AJ, Stellar E, eds, *Eating and its disorders*. New York: Raven Press, 1984, pp 97–107
96. Faust IM, Kral J: Growth of adipose tissue following lipectomy. In: Cryer A, Van RLR, eds, *New Perspectives in Adipose Tissue*. London: Butterworths, 1985, pp 319–332
- 97a. Fehér T, Bodrogi L: A comparative study of steroid concentration in human adipose tissue and the peripheral circulation. *Clin Chim Acta* **126**:135–141, 1982
- 97b. Fehér T, Bodrogi L, Vallent K, Ribai Z: Role of human adipose tissue in the production and metabolism of steroid hormones. *Endokrinologie* **80**(2): 173–180, 1982
98. Felig P, Marliss EL, Cahill JR: Metabolic response to hGH during prolonged fasting. *J Clin Invest* **50**: 411–421, 1971
99. Ferguson JH: *Learning to eat*. Palo Alto, CA: Bull Publishing Co., 1975
100. Ferin M, Van Vugt T, Wardlan S: The hypothalamic control of the menstrual cycle and the role of endogeneous peptides. *Rec Prog Horm Res* **40**:441–485, 1984
101. Festing MFW (Ed): *Animal models of obesity*. London: MacMillan, 1979
102. Fiddes JC, Talmadge K: Structure, expression and evolution of the genes for the human glycoprotein hormones. *Rec Prog Horm Res* **40**:43–78, 1984
103. Fischer A, Fischer GM: Revised technique for cellulitis fat reduction in riding-breeches deformity. *Bull Int Acad Cosmet Surg* **2**:40–42, 1977
104. Fleigelman R, Fried GH: Metabolic effects of human chorionic gonadotropin (hCG) in rats. *Proc Soc Exp Biol Med* **135**:317–319, 1970
105. Foley JE, Thuillez F, Bogardus C, Lilioja S, Motl D: Short-term overfeeding increases adipose cell number in moderately obese subjects. In: *Obesity and non-insulin dependent diabetes mellitus*. Joint Conference of the American Diabetes Association and the North American Association for the Study of Obesity. October 30–November 1, 1985, Abstract 120
106. Foreyt JP, Goodrick S, Gotto AM: Limitations of behavioral treatment of obesity: review and analysis. *Behav Med* **4**(2):159–174, 1981
107. Fournier PF, Otteni FM: Lipodissection in body

- sculpturing: The dry procedure. *Plast Reconstr Surg* **72**(5):598–609, 1983
108. Frank BW: The use of chorionic gonadotropin hormone in the treatment of obesity. *Am J Clin Nutr* **14**:133–136, 1964
 109. Friedman MH: Gonadotropic extracts from the leaves of young oak plants. *Proc Soc Exp Biol Med* **37**:645–646, 1938
 110. Friedman MH, Friedman GS: Gonadotropic extracts from green leaves. *Am J Physiol* **125**:486–490, 1939
 111. Friedrich F et al: Acute abdomen following hCG and hMG, *Wien Klin Wschr* **81**:318–320, 1969
 112. Frohman LA: The syndrome of hypothalamic obesity. In: Bray GA, ed, *Recent Advances in Obesity Research (II)*, New York: Newman Publishing Co., 1978, pp 133–141
 113. Fukata J, Nakai Y, Takahashi K, Imura H: Subcellular localization of IR- β -endorphin in rat hypothalamus. *Brain Res* **195**:489–493, 1980
 114. Van Gaal LF: Short and long-term effects of protein sparing modified fast (PSMF) very low calorie diets. *Abstr Vth Int Congr Obesity*, Jerusalem, 14–19 September, 1986, p 41
 115. Gambert SR, Garthwaite TL, Pontzer CH, Hagen TC: Fasting associated with decrease in hypothalamic β -endorphin. *Science* **210**:1271–1272, 1980
 116. Gamna C, Ceresa F: Le distrofie di origine diencefalo-ipofisaria. *Proc 51 Congr Med Int Ed*. Rome: Pozzi, 1950, p 34
 117. Garrow JS: Thermogenesis and obesity in man. In: Björntorp P, Cairella M, Howard A, eds, *Recent Advances in Obesity Research (III)*. London: John Libbey, 1981, pp 208–213
 118. Gerner RH, Catlin DON: Peripherally administered β -endorphin increases cerebrospinal fluid endorphin immunoreactivity. *J Clin Endocrinol Metab* **55**:358–360, 1982
 119. Gideon Wells H: Adipose tissue: a neglected subject. *J Am Med Assoc* **114**(22):2177–2183, 2284–2289, 1940
 120. Givens JR (ed): *The Hypothalamus*. Chicago: Year Book Medical Publisher, 1984
 121. Glennon JA: Weight reduction: an enigma. *Arch Int Med* **118**:1–2, 1966
 122. Gold DD Jr: Psychologic factors associated with obesity. *Am Fam Physician* **13**(6):87–91, 1976
 123. Goldrick RB, Havenstein N, Whyte HA: Effects of caloric restriction and fenfluramine on weight loss and personality profiles of patients with long-standing obesity. *Aust New Z J Med* **3**:131–141, 1973
 124. Goldwyn RM: The advent of liposuction (editorial) *Plast Reconstr Surg* **72**(5):705, 1983
 125. Gossman HH, Sandler Erpelt S: Constitution and obesity in adolescents. *Med Klin* **71**(46):2007–2012, 1976
 126. Grandison L, Guidotti A: Stimulation of food intake by muscimol and β -endorphin. *Neuropharmacology* **16**:533–536, 1977
 127. Gray H, Kallenbach DC: Obesity treatment: Results in 212 patients. *J Am Diet Assoc* **15**:239–245, 1939
 128. Grazer FM (ed): *Body Contour Surgery*. Clinics in Plastic Surgery. Philadelphia: W.B. Saunders, 1984, 11(3)
 129. Green MB, Beckman M: Obesity and its management. A survey of 671 patients. *Med rec* **160**:223–228, 1947
 130. Greenway FL, Bray GA: Human chorionic gonadotropin in the treatment of obesity. *West J Med* **127**:461–463, 1977
 131. Greenwood MRC, Cleary M, Steingrimsdottir L, Vasseli JA: Adipose tissue metabolism and genetic obesity: The LPL hypothesis. In: Björntorp P, Cairella M, Howard AN, eds, *Recent Advances in Obesity Research (III)*. London: John Libbey, 1981, pp 75–80
 132. Greenwood MRC: Adipose tissue: cellular morphology and development. *Ann Intern Med* **103**:996–999, 1985
 133. Grossman A: Brain opiates and neuroendocrine function. *J Clin Endocrinol Metab* **12**(3):725–746, 1983
 134. Grossman SP: Contemporary problems concerning our understanding of brain mechanisms that regulate food intake and body weight. In: Stunkard AJ, Stellar E, eds, *Eating and its disorder*. New York: Raven Press, 1984, pp 5–13
 135. Guggenheim FG: Basic considerations in the treatment of obesity. *Med Clin N Am* **61**(4):781–796, 1977
 136. Guillemin R: Peptides in the brain: the new endocrinology of the neuron. *Science* **202**:390–402, 1978
 137. Guillemin R: Personal communication, 1985
 138. Gulick, A: A study of weight regulation in the adult human body during over-nutrition. *Am J Physiol* **60**:371–397, 1922
 139. Hasimoto T, Sawai T: Chorionic gonadotropin as an analgesic. *Arch Int Med* **141**:269, 1981
 140. Hastrup B, Nielsen B, Skouby AP: Chorionic gonadotropin and the treatment of obesity. *Acta Med Scand* **168**(1):25–27, 1960
 141. Heady JA, Dalton M, Thorn J, Guinsburg J: Pain after intramuscular hCG. *Lancet* **II**:198, 1980
 142. Hervey GR, Tobin G: Luxusconsumption, diet-induced thermogenesis and brown fat: a critical review. *Clin Sci* **64**:7–18, 1983
 143. Hetherington, AW, Ranson SW: Experimental hypothalamohypophyseal obesity in the rat. *Proc Soc Exp Biol Med* **41**:465–466, 1939
 144. Hetherington AW, Ranson SW: Hypothalamic lesions and adiposity in the rat. *Anat Rec* **78**:149–172, 1940
 145. Hetter GP, Hermahn F: Experience with lipolysis: the Illouz technique of blunt suction lipectomy in North America. *Aesth Plast Surg* **7**:69–76, 1983
 146. Hetter GP: *Lipoplasty, the theory and practice of blunt suction lipectomy*. Boston: Little, Brown, 1984
 147. Hiragun A: Cell and tissue cultures models of adipocyte development. In: Cryer A, Van RLR, eds, *New Perspectives in adipose tissue: Structure, function and development*. London: Butterworths, 1985, pp 333–352
 148. Hirono M: The direct effect of hCG upon pituitary gonadotropin secretion. *Endocrinology* **90**:1214–1219, 1972
 149. Hirsch J, Knittle JL: Cellularity of obese and non-obese human adipose tissue. *Fed Proc* **29**:1516–1521, 1970
 150. Hirsch J, Van Itallie TB: The treatment of obesity. *Am J Clin Nutr* **26**:1039–1041, 1973

151. Hirsch J: Obesity, a perspective. In: Bray GA, ed, *Recent Advances in Obesity Research (II)*. London: Newman Publishing Co., 1978, pp 1–5
152. Ho TF, Chay SO, Yip WC, Tay JS, Wong HB: The prevalence of obesity in Singapore primary school children. *Aust J Pediatr* **19**(4):248–250, 1983
153. Hollander IJ, Ponte GE: Ectopic hormone production by malignant tumors. *Ann Clin Lab Sci* **9**(4):268–274, 1979
154. Houghten RA, Swann RW, Li CH: β -endorphin: stability clearance, behavior and entry into the CNS after intravenous injection of the titrated peptide in rats and rabbits. *Proc Natl Acad Sci (USA)* **77**(8):4588–4591, 1980
155. Howard AN: Safety and efficacy of the Cambridge diet. *Abstr Vth Int Congr Obesity*. Jerusalem, September 14–19, 1986, p 41
156. Huse DM, Branes LA, Colligan RC, Nelson RA, Palumbo PJ: The challenge of obesity in childhood. I: Incidence, prevalence and staging, *Mayo Clin Proc* **57**(5):279–284, 285–288, 1982
157. Hussa RO: Biosynthesis of Human Chorionic Gonadotropin. *Endocrinol Rev* **1**(3):268–294, 1980
158. Hustvedt BE, Jeszka J, Christophersen A, Løvø A: Energy metabolism in rats with VMH hypothalamic lesions. *Am J Physiol* **246**:E319–326, 1984
159. Illouz YG: Une nouvelle technique pour les lipodystrophies localisées. *Rev Chir Esthét Lang Fr* **6**:19–25, 1980
160. Illouz YG: Body contouring by lipolysis: a 5 year experience with over 3,000 cases. *Plast Reconstr Surg* **72**(5):591–597, 1983
161. Illouz YG: Remodelage chirurgical de la silhouette par lipolyse-aspiration ou lipectomie selective. *Ann Chir Plast Esthét* **29**(2):162–180, 1984
162. Illouz YG: Surgical remodelling of the silhouette by aspiration lipolysis or selective lipectomy. *Aesth Plast Surg* **9**:7–21, 1985
163. Innes JA, Munro JF, Campbell IW: Long-term followup after prolonged therapeutic starvation. In: Howard A, ed, *Recent Advances in Obesity Research (I)*. London: Newman Publishing Co., 1975, pp 348–349
164. Inoue S, Bray GA: An autonomic hypothesis for hypothalamic obesity. *Life Sci* **25**:561–566, 1979
165. Inoue S, Bray GA: Ventromedial hypothalamic obesity and autonomic nervous system: an autonomic hypothesis. In: Cioffi LA, James WPT, Van Itallie TB, eds, *The body weight regulatory system: normal and disturbed mechanisms*. New York: Raven Press, 1981, pp 61–64
- 166a. Itallie TB Van: Health implications of overweight and obesity in the United States. *Ann Intern Med* **103**:983–988, 1985
- 166b. Itallie TB Van, Abraham S: Some hazards of obesity and its treatment. In: Hirsch J, Van Itallie TB, eds, *Recent Advances in Obesity Research (IV)*. London: John Libbey, 1985, pp 1–19
167. James WPT, Trayhurn P: An integrated view of the metabolic and genetic basis for obesity. *Lancet* **II**(7989):770–772, 1976
168. James WPT, Trayhurn P: Genetic component of obesity (letter). *Lancet* **I**(8012):653–654, 1977
169. Jeanrenaud B: An overview of experimental models of obesity. In: Bray GA, ed, *Recent Advances in Obesity Research (II)*. London: Newman Publishing Co., 1978, pp 111–122
170. Jéquier E: L'obésité—dérèglement du bilan d'énergie. *Rev Med Suisse Rom* **100**:37–44, 1980
- 171a. Johnson ML, Burke BS, Mayer J: Incidence and prevalence of obesity in a section of school children in the Boston area. *Am J Clin Nutr* **4**:231–238, 1956
- 171b. Johnson ML, Burke BS, Mayer J: Relative importance of inactivity and overeating in the energy balance of obese school girls. *Am J Clin Nutr* **4**:37–44, 1956
172. Johnston FE: Health implications of childhood obesity. *Ann Intern Med* **103**:1068–1072, 1985
173. Jollifer N, Alpert E: "Performance index" as method for estimating effectiveness of reducing regimens. *Postgrad Med* **9**:106–115, 1951
174. Jung RT, James WP, Campbell RG, Callingham BA: Altered hypothalamic and sympathetic responses to hypoglycemia in familial obesity. *Lancet* **I**(8280):1043–1046, 1982
175. Kahana LH et al: Endocrine manifestations of intracranial extrasellar lesions. *J Clin Endocrinol Metab* **22**:304–324, 1962
176. Kaplan ML, Leveillee GA: Calorigenic response in obese and non-obese women. *Am J Clin Nutr* **29**:1108–1113, 1976
177. Kather H, Zollig G, Simon B, Schlierf G: Human fat cell adenylate cyclase, regional differences in adrenaline responsiveness. *Eur J Clin Invest* **7**:595–597, 1977
178. McKay LD, Kenney J, Williamsh R, Woods SC: Intracerebroventricular β -endorphin increases food intake in rats. *Life Sci* **29**:1429–1434, 1981
179. Keeseey RE, Boyle PC, Kemnitz JW, Mitchel JS: The role of the lateral hypothalamus in determining the body weight set-point. In: Novin D, Wrwicka W, Bray GA, eds, *Hunger, basic mechanisms and clinical implications*. New York: Raven Press, 1976, pp 243–255
180. Keeseey RE: A set-point analysis of the regulation of body weight. In: Stunkard AJ, ed, *Obesity*. Philadelphia: W.B. Saunders, 1980, pp 144–165
181. Keeseey RE, Corbett SW: Metabolic defense of the body weight set-point. In: Stunkard AJ, Stellar E, eds, *Eating and its disorders*. New York: Raven Press, 1984, pp 87–96
182. Keiller SM, Colley JR, Carpenter RG: Obesity in school children and their parents. *Ann Hum Biol* **6**(5):443–455, 1979
183. Kelly P, Sullivan D, Bartsch M, Gracey M, Ridout S: Evolution of obesity in young people in Busselton, Western Australia. *Med J Austr* **141**(2):97–99, 1984
184. Kemp R: The overall picture of obesity. *Practitioner* **209**:654–660, 1972
185. Kennedy GC: Hypothalamic control of food intake in rats. *Proc R Soc London B* **137**:535–549, 1950
186. Kesselring UK, Meyer R: Suction curette for removal of subcutaneous fat. *Plast Reconstr Surg* **62**:305–306, 1978
187. Kesselring UK: Suction curettage to remove excess fat for body contouring. *Plast Reconstr Surg* **69**:572, 1982
188. Kesselring UK: Regional fat aspiration for body contouring. *Plast Reconstr Surg* **72**(5):610–613, 1983

189. Kesselring UK: Aspirationslipektomie: eine Standortbestimmung. *Handchirurgie* **16**:115–117, 1984
190. Kirschner MA: A supplemented fasting program (VLCD) for control of major obesity: an eight-year experience. *Abstr Vth Int Cong Obesity*. Jerusalem, September 14–19, 1986, p 41
191. Kluthe R: Obesity in Europe. *Ann Intern Med* **103**:1037–1042, 1985
192. Knudtzon J: Hypoinsulinemic and hypoglycemic effects of β -endorphin in rabbits. *Horm Metab Res* **18**:505–509, 1986
193. Kohrs MB, Wang LL, Eklund D, Paulsen B, O'Neal R: The association of obesity with socioeconomic factors in Missouri. *Am J Clin Nutr* **32**(10):2120–2128, 1979
194. Kolata G: Obesity declared in disease. *Science* **227**(4690):1019–1020, 1985
195. Kopelman PG, White N, Pilkington TRE, Jeffcoate SL: Impaired hypothalamic control of prolactin secretion in massive obesity. *Lancet* **1**:747–749, 1979
196. Kopelman PG, Pilkington TRE, White N, Jeffcoate SL: Evidence for existence of two types of massive obesity. *Br Med J* **280**:82–83, 1980
197. Kowalczyk J: Analysis of familial, somatic and psychic aspects in children with simple obesity. *Pol Med Sci Hist Bull* **15**(1):65–69, 1976
198. Kraft K et al: Differential regulation of β -endorphin in the anterior pituitary, intermediate lobe, hypothalamus and brain stem. *Life Sci* **33**:491–494, 1983
- 199a. Kral J: Surgical reduction of adipose tissue cellularity in man. *Scan J Plast Reconstr Surg* **9**:140–143, 1975
- 199b. Kral J: Surgical reduction of adipose tissue cellularity. In: Howard A, ed, *Recent Advances in Obesity Research (I)*. London: Newman Publishing Co., 1975, pp 327–329
200. Krieger DT: Endorphins and enkephalins. *Disease-a-Month* July 10 1982
201. Krotkiewski M, Björntorp P, Sjöström L, Smith U: Impact of obesity on metabolism of men and women. Importance of regional adipose tissue distribution. *J Clin Invest* **72**:1150–1162, 1983
202. Krusinski MD: Telogen effluvium secondary to weight loss and therapy with chorionic gonadotropin. *Arch Dermatol* **112**:556, 1976
203. Lafontan M, Dang-Tran L, Berlan M: Alpha adrenergic antilipolytic effect of adrenaline in human fat cells of the thigh: comparison with adrenaline responsiveness of different fat deposits. *Eur J Clin Invest* **9**:261–266, 1979
204. Larsson B, Svarsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G: Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death. A 13-year follow-up in the study of men born in 1913. *Br Med J* **288**:1401–1408, 1984
205. Laskarzewski PM, Khoury P, Morrison JA, Kelly K, Mellies MJ, Glueck CJ: Familial obesity and leanness. *Int J Obes* **7**(6):505–527, 1983
206. Leibel RL, Hirsch J: Metabolic characterization of obesity (NIH consensus panel). *Ann Int Med* **103**:1000–1002, 1985
207. Levine AS, Yim GKW: Neuropeptidergic regulation of food intake. *Fed Proc* **43**:2888, 1984
208. Li CH: Personal communication, 1985
209. Liebelt R, Ichinose S, Nicholson N: Regulatory influences of adipose tissue on food intake and body weight. *Ann NY Acad Sci (USA)* **131**:559–582, 1965
210. Lilioja S, Foley J, Bogardus C, Mott D, Howard A: Free fatty acid metabolism in man. In vivo, in vitro comparisons. *Metabolism* **35**(6):505–514, 1986
211. Lindner PG, Blackburn GL: Multidisciplinary approach to obesity utilizing fasting modified by protein-sparing therapy. *Ob Bar Med* **5**:198–215, 1976
212. Linet OI: Long-term efficacy of medical treatments for obesity. *Klin Wschr* **60**:115–120, 1982
213. Livingston VW, Livingston AM: Some cultured immunological and biochemical properties of Progenitor cryptocides. *Trans NY Acad Sci USA* **36**(6):569–582, 1974
214. Le Magnen J: Neuroendocrine bases for the liporegulatory mechanism. In: Cioffi LA, James WPT, Van Itallie TB, eds, *The body weight regulatory system: normal and disturbed mechanisms*. New York: Raven Press, 1981, pp 315–321
215. Le Magnen J: Body energy balance and food intake: a neuroendocrine regulatory mechanism. *Physiol Rev* **63**(1):314–386, 1983
216. Mandenoff A, Fumeron F, Apfelbaum M, Margules DL: Endogenous opiates and energy balance. *Science* **215**:1536–1538, 1982
217. Margules DL: Obesity and the development of the diffuse neuro-endocrine system. *Int J Obes* **4**:296–303, 1980
218. Margules DL: Endorphinergic and endoloxinergic states of the diffuse neuroendocrine system in energy balance. In: Cioffi LA, James WPT, Van Itallie TB, eds, *The body weight regulatory system: normal and disturbed mechanisms*. New York: Raven Press, 1981, pp 361–368
219. Maruo T, Cohen H, Segal SJ, Koide SS: Production of chorio-gonadotropin-like factor by a microorganism. *Proc Natl Acad Sci USA* **76**:6622–6626, 1979
220. Matsumura M et al: Alteration in the levels of β -endorphin-like immunoreactivity in plasma and tissues of obese rats with hypothalamic lesions. *Horm Metab Res* **16**:105–106, 1984
221. Melichar V, Razôva M, Dyková H, Vizek K: Effect of human chorionic gonadotropin on blood free fatty acids, glucose and on the release of fatty acids from subcutaneous adipose tissue in various groups of newborns and adults. *Biol Neonate* **27**:80–87, 1975
222. Miller DS, Mumford P: Gluttony. 1. An experimental study overeating low or high-protein diets. *Am J Clin Nutr* **20**:1212–1219, 1967
223. Miller DS, Parsonage S: Resistance to slimming: adaptation or illusion? *Lancet* **1**:773–775, 1975
224. Miller R, Schneiderman LJ: A clinical study of the use of human chorionic gonadotropin in weight reduction. *J Fam Pract* **4**(3):445–448, 1977
225. Miller DS: Non-genetic models of obesity. In: Festing MFW, ed, *Animal models of obesity*. London: MacMillan, 1979, pp 131–140
226. Miller WH, Faust IM, Hirsch J: Demonstration of the novo production of adipocytes in adult rats by biochemical and radioautographic techniques. *J Lipid Res* **25**:336–347, 1984
227. Miyajima E, Buñag R: Anterior hypothalamic lesions impair reflex bradycardia selectively in rats. *Am J Physiol* **248**:937–944, 1985
228. Morley JF, Levine AS: The role of endogenous opi-

- ates as regulators of appetite. *Am J Clin Nutr* **35**: 757–761, 1982
229. Morley JE, Levine AS, Yim GKW, Lowy MT: Opioid modulation of appetite. *Neurosci Bio Behav Rev* **7**(2):281–305, 1983
 230. Morley JE, Levine AS, Gosnell BA, Billington CJ: Neuropeptides and appetite: contribution of neuropharmacological modelling. *Fed Proc* **43**: 2903–2907, 1984
 231. Naeye RL, Roode P: The size and numbers of cells in visceral organs in human obesity. *Am J Clin Pathol* **54**:251–253, 1970
 232. Neumann RO: Experimentelle Beiträge zur Lehre vom täglichen Nahrungsbedarf des Menschen unter besonderer Berücksichtigung der notwendigen Eiweissmenge. *Arch Hyg* **45**:1/89, 1902
 233. Neuwirth RS, Turksoy RN, Vande Wiele RL: Acute Meigs syndrome secondary to ovarian stimulation with ovarian human menopausal gonadotropins. *Am J Obstet Gynecol* **91**(7):977–981, 1965
 234. Newill R: Painful hCG injections. *Lancet* **II**:417–418, 1980
 235. NIH (National Institutes of Health, USA) consensus panel: Health implications of obesity. *Ann Intern Med* **103**:147–151, 1985
 236. Öberg K, Wide L: hCG and hCG subunits as tumor markers in patients with endocrine pancreatic tumors and carcinoids. *Acta Endocrinol* **98**:256–260, 1981
 237. Ohno M, Tsukahara S, Yokoyama J, Ikeda Y: Comparison of the two different VLCDs by observing degrees of weight reduction and nitrogen balance. *Abstr Vth Int Congr Obesity*. Jerusalem, September 14–19, 1986, p 78
 238. Olivecrona T, Bentsson G: Lipoprotein-lipase. In: Angel A, Hollenberg CH, Roncari DAK, eds, *The Adipocyte and obesity: Cellular and molecular mechanisms*. New York: Raven Press, 1983, pp 117–126
 239. Öst G, Götestam K: An experimental comparison between a behavioral and a pharmacological treatment of obesity. In: Howard A, ed, *Recent Advances in Obesity Research (I)*. London: Newman Publishing Co., 1975, p 316
 240. Östman J, Arner P, Kimura H, Wahranberg H, Engfeldt P: Effect of therapeutic fasting on alpha and beta-adrenergic receptors in subcutaneous adipose tissue. Quoted in: Arner P: Site differences in human subcutaneous adipose tissue metabolism in obesity. *Aesth Plast Surg* **8**:13–17, 1984
 241. Otteni FM, Fournier PF: A history and comparison of suction techniques until their debut in North America. In: Hetter GO, ed, *Lipoplasty—The theory and practice of blunt suction lipectomy*. Boston: Little, Brown, 1984, pp 19–24
 242. Pala A, Marinelli G, Di Gregorio R, Spampinato G, Moro M, Carenza L: Substantial amounts of gonadotropin-like materials in sera of normal subjects. *J Endocrinol* **91**:179–188, 1981
 243. Panksepp J: Hypothalamic regulation of energy balance and feeding behavior. *Fed Proc* **33**(5):1150–1165, 1974
 244. Passmore R: The regulation of body weight in man. *Proc Nutr Soc* **30**:122–127, 1971
 245. Pawson IG, Janes C: Massive obesity in a migrant Samoan population. *Am J Public Hlth* **71**(5):508–513, 1981
 246. Pequignot G, Vinit F, Richard JL, Cubeau J, Papoz L, Laquerriere A: Rations alimentaires et embonpoint. In: Apfelbaum M, ed, *Energy balance in man*. Paris: Masson et Cie, 1973, pp 61–64
 247. Perelberg H: Chorionic gonadotropin and obesity. *Med J Austr* **64**(2):68–69, 1977
 248. Pickar D, Dubois M, Cohen MR: Behavioral change in a cancer patient following intrathecal β -endorphin administration. *Am J Psych* **141**:103–104, 1984
 249. Pierce JG: Eli Lilly Lecture: The subunits of pituitary thyrotropin—their relationships to other glycoprotein hormones. *Endocrinology* **89**:1331–1344, 1971
 250. Pitman GH, Teimourian B: Suction lipectomy: complications and results by survey. *Plast Reconstr Surg* **76**(1):65–69, 1985
 251. Powley TL, Opsahl CA, Cox JE, Weingarten HP: The role of the hypothalamus in energy homeostasis. In: Morgane PJ, Panksepp J, eds, *Handbook of the hypothalamus*. New York: Marcel Dekker, 1980, Vol 3, pp 211–298
 252. Rand C, Stunkard AJ: Obesity and psychoanalysis. *Am J Psych* **135**(5):547–551, 1978
 253. Ravelli GP, Stein ZA, Susser MW: Obesity in young men after famine exposure in utero and early infancy. *N Engl J Med* **295**(7):349–353, 1976
 254. Rebuffè-Scrivè M et al: Fat cell metabolism in different regions in women. Effect of menstrual cycle/pregnancy and lactation. *J Clin Invest* **75**(6):1973–1976, 1985
 255. Richter WO, Schwandt P: Peptide hormones and lipolysis in rabbits adipocytes. *Horm Metab Res* **17**(3):127–130, 1985
 256. Rivlin RS: Therapy of obesity with hormones. *N Engl J Med* **Jan 2**:26–29, 1975
 257. Robinson DS, Parkin SM, Speake BK, Little JA: Hormonal control of rat adipose tissue lipoprotein lipase activity. In: Angel A, Hollenberg CH, Roncari DAK, eds, *The Adipocyte and metabolism: Cellular and molecular mechanisms*. New York: Raven Press, 1983, pp 127–136
 258. Rodin J: Psychological factors in obesity. In: Björntorp P, Cairella M, Howard AN, eds, *Recent Advances in Obesity Research (III)*. London: John Libbey, 1981, pp 106–123
 259. Roe DA, Eickwort KR: Relationships between obesity and associated health factors with unemployment among low income women. *J Am Med Women Assoc* **31**(5):193–194, 198–199, 203–204, 1976
 260. Romer TE: The influence of gonadotropins on corticosteroids and some histochemical reactions in the brown fat tissue of white rat. *Endocrinol Polska* **17**: 297–305, 1966
 261. Rona RJ, Chinn S: Natural study of health and growth: social and family factors and obesity in primary school children. *Ann Hum Biol* **9**(2):131–145, 1982
 262. Roncari DAK, Lau DCW, Djian PH, Kindler S, Yip DK: In: Angel A, Hollenberg CH, Roncari DAK, eds, *Culture and cloning of adipocyte precursors from lean and obese subjects: Cellular and molecu-*

- lar mechanisms. New York: Raven Press, 1983, pp 65–73
263. Ross GT: Clinical relevance of research on the structure of human chorionic gonadotropin. *Am J Obstet Gynecol* **129**:795–808, 1977
 264. Roth J, Greenwood MRC, Johnson PR: The regenerating fascial sheath in bipectomized Osborne–Mendel rats: morphological and biochemical indices of adipocyte differentiation and proliferation. *Int J Obes* **5**:131–143, 1981
 265. Ruddon RW, Bryan AH, Hanson CA, Perini F, Ceccorulli LM, Peters BP: Production of hCG and its subunits by human tumors growing in mice. *Cancer Res* **40**:4007–4012, 1980
 266. Ruddon RW, Bryan AH, Hanson CA, Perini F, Ceccorulli LM, Peters BP: Characterization of the intracellular and secreted forms of hCG produced by human malignant cells. *J Biol Chem* **256**(10):5189–5196, 1981
 267. Ruderman NB, Berchtold P, Schneider S: Obesity-associated disorders in normal weight individuals: some speculations. *Int J Obes* **6**:151–157, 1982
 268. Salans LB, Horton ES, Sims EAH: Experimental obesity in man—cellular character of adipose tissue. *J Clin Invest* **50**:1005–1011, 1971
 269. Salans LB, Cushman SW, Weissman RE: Study on adipose tissue. Adipose cells size and number in non-obese and obese patients. *J Clin Invest* **52**:929–941, 1973
 270. Sanger DJ: Endophinergic mechanisms in the control of food intake. *Appetite* **2**(3):193–208, 1981
 271. Schally AV, Coy DH, Meyers CA: Hypothalamic regulatory hormones. *Ann Rev Biochem* **47**:89–128, 1978
 272. Schneider BS, Hirsch J: Hypothalamic-pituitary function in obesity. In: Freinkel N, ed, *Contemporary Metabolism*. New York: Plenum Medical Book Co., 1982, pp 119–144
 273. Schrudde J: Lipexeresis in the correction of local adiposities. *Proc 3rd Int Congr Int Soc Aesth Plast Surg*, Rio de Janeiro, 1972
 274. Schwartz RS, Brunzell JD: Adipose tissue lipoprotein lipase and obesity. In: Björntorp P, Cairella M, Howard AN, eds, *Recent Advances in Obesity Research (III)*. London: John Libbey, 1981, pp 94–98
 275. Segal SJ ed: *Chorionic Gonadotropin*. New York: Plenum, 1980
 276. Shetty KR, Kalkhoff RK: Human chorionic gonadotropin treatment of obesity. *Arch Intern Med* **137**:151–155, 1977
 277. Shetty PS, Jung RT, James WPT, Barrand SA, Calingham BA: Postprandial thermogenesis in obesity. *Clin Sci* **60**:519–525, 1981
 278. Simeons ATW: The action of chorionic gonadotropin in the obese. *Lancet* **II**:946–947, 1954
 279. Simeons ATW: *Pounds and Inches: a new approach to obesity*. Private printing, 1974
 280. Sims EAH, Danforth E Jr, Horton ES, Bray GA, Glennon JA, Salans LB: Endocrine and metabolic effects of experimental obesity in man. *Rec Prog Horm Res* **29**:457–496, 1973
 281. Sims EAH: Experimental obesity, dietary-induced thermogenesis and their clinical implications. *J Clin Endocrinol Metab* **5**(2):377–395, 1976
 - 282a. Sjöström L: Can the relapsing patient be identified? In: Björntorp P, Cairella M, Howard AN, eds, *Recent Advances in Obesity Research (III)*. London: John Libbey, 1981, pp 85–93
 - 282b. Sjöström L, William Olson T: Prospective studies on adipose tissue development in man. *Int J Obes* **5**:597–604, 1981
 283. Sjöström L: A review of weight maintenance and weight changes in relation to energy metabolism and body composition. In: Hirsch J, Van Itallie TB, eds, *Recent Advances in Obesity Research (IV)*. London: John Libbey, 1985, pp 82–94
 284. Slifkin M, Pardo M, Pouchet-Melvin GR, Acevedo HF: Immuno-electron microscopic localization of a choriogonadotropin-like antigen in cancer-associated bacteria. *Oncology* **36**:208–210, 1979
 285. Smith GP, Gibbs J: Gut peptides and postprandial satiety. *Fed Proc* **43**:2889–2892, 1984
 286. Smith OA: Food intake and hypothalamic stimulation. In: Sheer D, ed, *Electrical stimulation of the brain*. Dallas: Univ Texas P, 1961, pp 3–17
 287. Smith U: Human fat cell metabolism. In: Bray GA, ed, *Recent Advances in Obesity Research (II)*. London: Newman Publishing Co., 1978, pp 190–195
 288. Smith U: Regional differences in adipocyte metabolism and possible consequences “in vivo”. In: Hirsch J, Van Itallie TB, eds, *Recent Advances in Obesity Research (IV)*. London: John Libbey, 1985, pp 33–36
 289. Sohar E: A forty-day 550-calorie diet in the treatment of obese outpatients. *Am J Clin Nutr* **7**:514–518, 1959
 290. Somogy JC: The role of low calorie foods in weight reduction. *Abstr Vth Int Congr Obesity*. Jerusalem September 14–19, 1986, p 78
 291. Stabile BE, Braunstein GD, Vassaro E: Serum gastrin and human chorionic gonadotropin in the Zollinger–Ellison syndrome. *Arch Surg* **115**:1090–1095, 1980
 292. Stark O, Lloyd JK, Wolff OH: Long-term results of hospital inpatient treatment of obese children. In: Howard A, ed, *Recent Advances in Obesity Research (I)*. London: Newman Publishing, 1975, p 289
 293. Stefanik PA, Heald FP, Mayer J: Caloric intake in relation to energy output of obese and nonobese adolescent boys. *Am J Clin Nutr* **7**:55–62, 1956
 294. Stein MR, Julis RE, Peck CC, Hinshaw W, Sawicki JE, Deller JJ: Ineffectiveness of human chorionic gonadotropin in weight reduction: a double blind study. *Am J Clin Nutr* **29**:940–948, 1976
 295. Stellar E: The physiology of motivation. *Psychol Rev* **61**:5–22, 1954
 296. Stellar E: Neural basis: Introduction. In: Stunkard AJ, Stellar E, eds, *Eating and its disorders*. New York: Raven Press, 1984, pp 1–3
 297. Stern JS: Genetic influences in the development of obesity: focus on food intake. *Int J Obes* **4**(4):304–309, 1980
 298. Stirling JL, Stock MJ: Nonconservative mechanisms of energy metabolism in thermogenesis. In: Apfelbaum M, ed, *Energy balance in man*. Paris: Masson et Cie, 1973, pp 219–226
 299. Stuart RB: Behavioral control of overeating. *Behav Res Ther* **5**:357–365, 1967
 300. Stunkard AJ, McLaren-Hume M: The results of treatment for obesity. *Arch Intern Med* **103**:79–85, 1959

- 301a. Stunkard AJ: Obesity and the social environment. In: Howard A, ed, *Recent Advances in Obesity Research (I)*. London: Newman Publishing Co, 1975, pp 178–190
- 301b. Stunkard AJ: From explanation to action in psychosomatic medicine: The case of obesity. *Psychosom Med* **37**:195–230, 1975
302. Stunkard AJ, Craighead LW, Brownell KD: Behavior therapy of obesity: comparison with pharmacotherapy and combined treatment. In: Björntorp P, Cairella M, Howard AN, eds, *Recent Advances in Obesity Research (III)*. London: John Libbey, 1981, pp 190–198
303. Stunkard AJ, Wadden TA: Behavior therapy and obesity. In: Conn HL, De Felice EA, Kuo P, eds, *Health and Obesity*. New York: Raven Press, 1983, pp 105–130
304. Stunkard AJ et al: An adoption study of human obesity. *N Engl J Med* **314**(4):193–198, 1986
305. Suginami H, Kawaoi A: Immunohistochemical localization of a human chorionic gonadotropin-like substance in the human pituitary gland. *J Clin Endocrinol Metab* **55**:1161–1166, 1982
306. Taniguchi A et al: Regional differences in carboxylesterase activity between human subcutaneous and omental adipose tissue. *Life Sci* **36**:1465–1471, 1985
307. Taymor M: Gonadotropin therapy: Possible causes and prevention of ovarian hyperstimulation. *J Am Med Assoc* **203**(5):362–363, 1968
- 308a. Teimourian B, Adham MN, Gulin S, Shapiro C: Suction lipectomy. A review of 200 patients over a six year period and a study of the technique in cadavers. *Ann Plast Surg* **11**(2):93–98, 1983
- 308b. Teimourian B: Face and neck suction-assisted lipectomy associated with rhytidectomy. *Plast Reconstr Surg* **72**(5):627–633, 1983
309. Tell GPE, Haour F, Saez JM: The interaction of hCG with rat adipose tissue: apparent lack of hCG-LH receptors. *Mol Cell Endocrinol* **6**:171–179, 1977
310. Tischler ME, Goldberg AL: Leucine degradation and release of glutamine and alanine by adipose tissue. *J Biol Chem* **255**(17):8074–8081, 1980
311. Trozak DJ: Hair loss after therapy with chorionic gonadotropin. *Arch Dermatol* **112**:1035, 1976
312. Vague J: La différentiation sexuelle: facteur déterminant de formes de l'obésité. *Presse Méd* **30**:339–340, 1947
313. Vague J: Degree of masculine differentiation of obesity: factor determining predisposition to diabetes, arteriosclerosis, gout and uric acid calculous disease. *Am J Clin Nutr* **4**:20–34, 1956
314. Vague J, Fenasser R: Comparative anatomy of adipose tissue. *Handbook of physiology*. Section 5: Adipose Tissue. Washington, DC: Physiol Soc, 1965, pp 25–36
315. Vague J, Meignen JM, Negrin JF: Effects of testosterone and estrogens on deltoid and throcantheric adipocytes in two cases of transsexualism. *Horm Metab Res* **16**:380–381, 1984
316. Vague J, Vague P, Meignen JM, Jubelin J, Tramon M: Android and gynoid obesity. Past and present. In: Vague J, Björntorp P, Guy-Grand B, Rebuffé-Scrive M, Vague P, eds, *Metabolic Complications of human obesities*. Excerpta Medica Int Congr Ser 682. The Netherlands: Elsevier, 1985, pp 3–11
317. Vaitukaitis JL, Ross GT, Braunstein GD: Gonadotropins and their subunits: basic and clinical studies. *Rec Prog Horm Res* **32**:289–331, 1976
318. Vaitukaitis JL: Glycoprotein hormones and their subunits—immunological and biological characterization. In: McKerns KW, ed, *Structure and function of the gonadotropins*. New York: Plenum, 1978, pp 339–360
319. Vogt T: A combined medico-surgical approach to the treatment of obesity. XI Instructional Course, ISAPS. Lausanne, Switzerland, June 28–July 1, 1978
- 320a. Vogt T: Der Chirurg als Bildhauer: Idealfigur durch das Skalpell? *Med Trib* **45**:84–88, 1979
- 320b. Vogt T: Combined medico-surgical torsioplasty. *Trans VIIth Int Congr Plast Reconstr Surg*, Rio De Janeiro, Brasil, May 20–25, 1979, pp 513–516
- 321a. Vogt T: Medizinisch-chirurgische Gesamtkörper-Plastik. *Méd Hyg* **38**:1040–1045, 1980
- 321b. Vogt T: Combined medico-surgical torsioplasty. *Aesth Plast Surg* **4**:109–115, 1980
322. Vogt T, Dicksheet S: Suction curettage and alternatives to remove excess fat (letter). *Plast Reconstr Surg* **69**:724, 1982
323. Vogt T: Functional and aesthetic results following body contour surgery. *Trans VIIIth Int Congr Plast Surg*, Montreal, June 26–July 1, 1983, p 753
324. Vogt T: Alternativtherapien für Patienten, die für die Aspirationslipektomie ungeeignet sind. 14th Jahr Verein Dtsch Plast Chir, München, September 26–29, 1984
325. Vogt T, Belluscio DO: Controversial methods in obesity therapy. Experiences in relation to plastic surgery in a Swiss clinic. 35th Ann Symp Am Soc Bariat Physicians, Las Vegas, October 23–26, 1985
326. Voukidis TE: Reply to suction lipectomy (letter). *Plast Reconstr Surg* **75**(1):137, 1985
327. Wadden TA, Stunkard AJ, Vrownell KD, Day SC: Advances in the treatment of moderate obesity: combined treatment by behavior modification and very-low-calorie diet. In: Hirsch J, Van Itallie TB, eds, *Recent Advances in Obesity Research (IV)*. London: John Libbey, 1985, pp 312–319
328. Whitelaw AG: Influence of maternal obesity in subcutaneous fat in the newborn. *Br Med J* **1**(6016):985–986, 1976
329. Williams RR: The role of genetic analysis in characterizing obesity. *Int J Obes* **8**(5):551–559, 1984
330. Wilson RR, Brownell K: Behavior therapy for obesity: an evaluation of treatment outcome. *Adv Behav Ther Res* **3**:49–86, 1980
331. Wing RR, Jeffery RW: Outpatient treatment of obesity: a comparison of methodology and clinical results. *Int J Obes* **3**:261–279, 1979
332. Woods SC, Taborsky GJ, Porte D Jr: Central nervous system control of nutrient homeostasis. In: Mountcastle VB, Bloom FE, Geiger SR, eds, *Handbook of Physiology*. Section I. Volume IV: Intrinsic Regulatory Systems of the Brain. Bethesda, MD: Am Physiol Soc 1986, pp 365–411
333. Yaginuma T: Uptake of labelled human chorionic gonadotropin in the brain of the adult female rat. *Acta Endocrinol* **71**:245–254, 1972
334. Yanagihara Y: Experimental study on the effect of gonadotropic hormone on carbohydrate and lipid metabolism in pregnancy. Report III: The effect of carbohydrate and lipid metabolism in pregnant rats

- of fat emulsion and gonadotropic hormone simultaneously administered in starvation. *J Jpn Obstet Gynecol Soc* **15**(2):109, 1968
335. [Yim GKW, Lowy MT: Opioids, feeding and anorexias. *Fed Proc* **43**:2893. 2897, 1984](#)
336. [Yoshimoto Y, Wolfsen AR, Hirose F, Odell WD: Human chorionic-like material: presence in normal human tissues. *Am J Obstet Gynecol* **134**\(7\):729–733, 1979](#)
337. [Young RL, Fuchs RJ, Woltjen MJ: Chorionic Gonadotropin in weight control. *J Am Med Assoc* **236**\(22\):2495–2497, 1976](#)
338. [Zondek B, Sulman F: The mechanism of action and metabolism of gonadotrophic hormones in the organism. *Vit Horm* **3**:297–336, 1945](#)
339. [Zwiauer KF, Wildhalm KM: Die Entwicklung der Fettsucht im Kindesalter. *Klin Pädiatr* **196**\(6\):327–335, 1984](#)